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ABSTRACT 
Introduction: Patients with severe chronic diseases and 
advanced cancer in Palliative care, have a complex array of 
physical and psychosocial needs that can arise early in the 
course of illness. Palliative care therapies are well-placed to 
address those needs; however, referrals to the psychosocial 
interventions in palliative care are typically made late in the 
illness trajectory. We studied 2 groups of patients with severe 
chronic illnesses who participated in a non-randomized trial of 
early integration in palliative care of clinical hypnosis, versus 
standard pharmacological care. The purpose of the present 
investigation was to evaluate whether a long term intervention 
with clinical hypnosis and self-hypnosis as adjuvant therapy in 
chronic pain and anxiety, is more effective than only a therapy 
with medicines. 
Materials and Methods: The study was performed at the 
comprehensive Center for Pain Therapy at the University of 
Verona, Italy. This is a nonrandomized trial. A total of 50 
patients were studied in two groups: 25 in a group therapy with 
the hypnosis intervention as adjuvant therapy to medicines, 25 in 
a control group, who received only a pharmacological 
intervention. Evaluations with VAS scale for pain and HAMA 
Hamilton anxiety scale for anxiety were conducted for a long-
term follow-up. Subjects were assessed at the first session, after 
one year and two years’ follow-up.   
Results: Fifty subjects 14 men and 36 women participated to the 
study. The patients suffered from 3 main types of severe chronic 
disease: rheumatic (n=21), neurologic (n=16) and oncologic 
(n=13). Sixteen of them (32%) were administered with opioids 
for pain control. Half of the patients (n=25) were assigned to the 
group administered with the self-hypnotic protocol (hypnosis 
group), while the remaining 25 followed the conventional pain 
therapies (control group). The two groups were homogeneous in 
the distribution of age, sex, type of disease, and use of opioids at 
baseline. Subjects administered with the hypnosis therapy had a 
greater reduction in pain and in anxiety. The VAS score at 
baseline was similar between the hypnosis and the control group 
(mean ± standard deviation, sd: 78 ± 16 and 77 ± 14, 
respectively); after 1 year and 2 years, the score decreased in 
both groups compared to baseline score, but it was lower in the 
hypnosis group compared to the control group (62 ± 15/control; 
and 46 ± 14/hypnosis, respectively). The Hamilton score in 
multivariate analysis, the treatment with hypnosis was 
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associated with a greater decrease of 7 points compared to the 
control group, independently from the score at baseline. The 
decrease in VAS and Hamilton score were studied in the two 
therapy groups according to the type of disease suffered by the 
patients: rheumatic disease, neurologic disease, or cancer. For 
all the 3 types of disease, the reduction in both VAS and 
Hamilton scores was significantly greater in the subjects who 
were included in the hypnosis group, after 1 and 2 years follow-
up. Subjects in the hypnosis group were at lower risk of 
increasing the pharmacological treatment for pain control. The 
group 1 (hypnosis) after a long term follow-up 1 and 2 years of 
treatment with hypnosis as an adjuvant therapy for pain and 
anxiety, shows a significant statistical decrease of pain and 
anxiety compared with the control group. 
Conclusions The themes resulting from the statistical analysis 
fell into 3 categories: the decrease of pain, the decrease of 
anxiety, and the decrease of the use of the opioids. In the 
hypnosis group, the focus of care in the palliative care of the 
severe chronic illnesses, was perceived to be disease-centered, 
with emphasis on controlling physical and psychological pain 
and anxiety.  
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CHAPTER 1 
 
 
 
INTRODUCTION AND SCIENTIFIC BACKGROUND 
 
 
 
PAIN AND ANXIETY IN SEVERE CHRONIC DISEASES 
AND IN PALLIATIVE CARE: RECENT ADVANCES IN 
THE APPLICATION OF HYPNOSIS FOR SYMPTOM 
MANAGEMENT. 
 
 
 
In scientific literature, clinical hypnosis is considered as a 
psychological intervention and as a CAM in pain therapy and in 
Palliative Vare (Stoelb BL, Molton IR, Jensen MP, Patterson 
DR., 2009; Jensen MP., 2009; Brugnoli MP, 2014; Elkins, G., 
2007). 
Clinical Hypnosis in cancer and in severe chronic diseases, is 
practiced for both chronic pain and anxiety conditions:  
(1) hypnotic analgesia consistently results in greater decreases in 
a variety of pain outcomes compared to no treatment/standard 
care;  
(2) hypnosis reliefs anxiety-related outcomes in Palliative Care;  
(3) hypnosis can reduce the use of opioids in chronic severe 
diseases and in palliative Care (Stoelb BL, Molton IR, Jensen 
MP, Patterson DR., 2009; Jensen MP., 2009; Brugnoli MP, 
2014). 
In severe chronic illnesses and in Palliative Care, when we 
cannot cure the illnesses, we can improve the well-being of the 
patients in the context of chronic or life-threatening illness as a 
patient-reported outcome consisting of growth or benefit in 
psychological, social, and/or spiritual dimensions representing 
improvement well above the patient’s pre-morbid baseline.   
This positive outcome often occurs despite substantial suffering 
during the illness, even in terminal cases. 
Kearney (2000) contrasted the “treatment for pain” and “healing 
of suffering” perspectives in palliative care.  He characterizes 
the “treatment for pain” perspective as seeing pain only as a 
9 
 
medical condition that can be assessed, treated, and in the vast 
majority of instances brought under control.  In this perspective, 
relief from pain is reliant on the knowledge, skill, and 
intervention of a skilled practitioner. Kearney points out that 
many forms of suffering (such as grief) persist despite 
substantial efforts made by expert caregivers and by the patients 
themselves.   
Saunders (1996) observed that the whole experience of a 
patient’s life was reflected in that patient's dying.  She advocated 
the concept of “total pain,” a complex of physical, emotional, 
psychological, social, and spiritual factors.  In her view, total 
pain can include not only physical pain but also psychological 
pain (e.g., anxiety, depression, and fear), social pain (e.g., 
concern for their family including bereavement), and/or spiritual 
pain (e.g., a need to find some meaning in the situation, some 
deeper reality in which to trust).  
A large number of studies have provided evidence for the 
efficacy of clinical hypnosis and self-hypnosis, as a 
psychological intervention as an adjuvant therapy- add to 
therapy-, in the treatment of chronic pain, anxiety and anxiety-
related symptoms in severe chronic illnesses. Hypnosis practice 
is increasingly being employed in Western psychology to 
alleviate a variety of mental and physical conditions. Scientific 
research into hypnosis generally falls under the umbrella of 
positive psychology, but hypnosis is much more. Research has 
been ongoing over the last twenty or thirty years, with a surge of 
interest over the last decade in particular.  
However, the scientific literature lacks for long term follow-up 
(1 year and 2 year) to evaluate the efficacy of hypnosis for pain 
and anxiety relief in severe chronic illnesses and in Palliative 
Care. The purpose of this study was to investigate the efficacy of 
hypnosis and self-hypnosis to relief pain and anxiety, as 
adjuvant therapy, in severe chronic illnesses for a long-term 
follow up: 1 year and 2 year. 
Palliative care is an approach that improves the quality of life of 
patients and their families facing the problem associated with 
life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual. Palliative care: 
 provides relief from pain and other distressing symptoms; 
 affirms life and regards dying as a normal process; 
 intends neither to hasten or postpone death; 
 integrates the psychological and spiritual aspects of patient care; 
 offers a support system to help patients live as actively as possible until 
death; 
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 offers a support system to help the family cope during the patients illness 
and in their own bereavement; 
 uses a team approach to address the needs of patients and their families, 
including bereavement counselling, if indicated; 
 will enhance quality of life, and may also positively influence the course 
of illness; 
 is applicable early in the course of illness, in conjunction with other 
therapies that are intended to prolong life, such as chemotherapy or 
radiation therapy, and includes those investigations needed to better 
understand and manage distressing clinical complications. 
Chronic severe diseases are the diseases that persist for a long 
time. A chronic disease is one lasting 3 months or more, by the 
definition of the U.S. National Center for Health Statistics. 
Chronic diseases generally cannot be prevented by vaccines or 
cured by medication, nor do they just disappear. Chronic 
diseases tend to become severe and more common with age. The 
leading chronic diseases in developed countries include: arthritis 
and severe chronic rheumatic diseases, cardiovascular diseases, 
neurological chronic diseases and stroke, cancer such 
as breast and colon cancer and other chronic diseases 
as diabetes, obesity, and other health problems (CDC/National 
Center for Health Statistics, 2015; WHO, 2002). Chronic 
diseases are the leading causes of death and disability 
worldwide.  
The chronic care model (CCM) describes chronic care as “the 
prevention and diagnosis, management, and palliation of chronic 
disease” and is internationally accepted as the main strategic 
response to the challenges of chronic disease. The model calls 
for the redesign of health care to provide continuous, 
coordinated multi-faceted systems of health service delivery. 
The CCM is based on a Cochrane systematic review of chronic 
care interventions (Wagner EH, Austin BT, Davis C, Hindmarsh 
M, Schaefer J, Bonomi A., 2001; Wagner EH., 1998; McKenna 
MT, Taylor WR, Marks JS, Koplan JP., 1998).   
 
Pain and Suffering in severe chronic diseases and in 
Palliative Care  
 
The often quoted IASP definition of pain as "an unpleasant 
sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage." 
The inability to communicate verbally does not negate the 
possibility that an individual is experiencing pain and is in need 
of appropriate pain-relieving treatment. 
Pain and suffering are universal human experiences.  
Serious chronic illnesses are a major health issue in modern 
society. In chronic disease anxiety/depression, self-focused 
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attention, pain and suffering, are significant predictors of panic-
fear symptoms, lower self-efficacy, and more perceived 
interference in wellbeing of the patient. Pain and suffering are 
always subjective (IASP, 2009). 
Pain is a complex phenomenon involving both neurophysiologic 
and psychological components.  
The neuromatrix theory of pain proposes that pain is a 
multidimensional experience produced by characteristic 
"neurosignature" patterns of nerve impulses generated by a 
widely distributed neural network-the "body-self neuromatrix"-
in the brain (Melzack R., 2005). These neurosignature patterns 
may be triggered by sensory inputs, but they may also be 
generated independently of them.  
The neuromatrix theory of pain provides a new conceptual 
framework to examine these problems. It proposes that the 
output patterns of the body-self neuromatrix activate perceptual, 
homeostatic, and behavioral programs after injury, pathology, or 
chronic stress. Pain, then, is produced by the output of a widely 
distributed neural network in the brain rather than directly by 
sensory input evoked by injury, inflammation, or other 
pathology. The neuromatrix, which is genetically determined 
and modified by sensory experience, is the primary mechanism 
that generates the neural pattern that produces pain. Its output 
pattern is determined by multiple influences, of which the 
somatic sensory input is only a part, that converge on the 
neuromatrix (Melzack R., 2005). 
Pathophysiological mechanisms involve neural pathways, and a 
variety of pain-producing substances and modulating 
mechanisms. These include acetylcholine, serotonin, histamine, 
bradykinin, prostaglandins, substance P, somatostatin, 
cholecystokinin, vasoactive intestinal polypeptide, noradrenaline 
and endogenous opioid peptides. The opioid system controls 
pain, reward and addictive behaviors. Opioids exert their 
pharmacological actions through three opioid receptors, mu, 
delta and kappa whose genes have been cloned (Oprm, Oprd1 
and Oprk1, respectively). Opioid receptors in the brain are 
activated by a family of endogenous peptides like enkephalins, 
dynorphins and endorphin, which are released by neurons 
(Contet CS, Kieffer BL, Befort K, 2004).   
In assessing patients with pain, it is essential to evaluate the 
cause of the pain, its severity, type, location, duration, quality, 
and response to therapies, among other factors (Lasagna L., 
1986). It is the perception of pain and the individual’s physical 
and emotional reaction to the pain perception that give us the 
opportunity to create treatment approaches that can provide 
relief.  
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Complex psychological factors play an important role in the 
variability of perceived pain (Aoki J, Ikeda K, Murayama O, 
Yoshihara E, Ogai Y, Iwahashi K., 2010). 
The patient with pain in chronic diseases and in Palliative Care, 
should be reassured; it is understood that the patient is suffering, 
and an appropriate cause for this suffering and the most effective 
treatment will be sought. The physicians can offer a useful 
service in the diagnosis and treatment of pain in many complex 
cases. 
In 1994, responding to the need for a more useful system for 
describing chronic pain, the International Association for the 
Study of Pain (IASP) classified pain according to specific 
characteristics: (1) region of the body involved (e.g. abdomen, 
lower limbs), (2) system whose dysfunction may be causing the 
pain (e.g., nervous, gastrointestinal), (3) duration and pattern of 
occurrence, (4) intensity and time since onset, and (5) etiology.  
There are two basic types of pain: acute and chronic. 
Acute pain occurs for brief periods of time and is associated 
with temporary disorders. However, it is always an alarm signal 
that something may be wrong. 
Chronic pain is continuous and recurrent. It is associated with 
chronic diseases and is one of their symptoms.  
Pain intensity not only depends on the type of stimulus that 
caused it, but also on the subjective perception of the pain. 
Difficulty in maintaining the balance between adequate pain 
relief and acceptable tolerability, particularly with strong 
opioids, can lead to the establishment of a “vicious circle” that 
alternates between lack of efficacy and unpleasant side effects, 
prompting discontinuation of treatment.  
Pain management in patients due to aged heterogeneity, 
multimorbidity, and polypharmacy; selection of treatment in an 
effort to maximize patients' functional abilities in addition to 
relieving their pain (Schmader KE, Baron R, Haanpää ML, 
Mayer J, O'Connor AB, Rice AS, Stacey B., 2010). 
The interplay between pain and therapy is very complex, in that 
pain may be a target for treatment, but can also have negative 
effects on therapy procedures. Moreover, side effects of drugs, 
which are currently used to treat pain, may negatively influence 
the therapy and rehabilitation outcomes in severe chronic 
illnesses and in Palliative Care.  
Because of the lack of guidelines or consensus, the Italian 
Consensus Conference on Pain in Neurorehabilitation (ICCPN) 
was aimed to answer some open questions on the treatment of 
pain in this setting. To this aim, they collected evidence on the 
pharmacological and non-pharmacological strategies and their 
role in the integrated approach to pain (Tamburin S, Lacerenza 
MR, Castelnuovo G, Agostini M, Paolucci S, Bartolo et Al, 
M, Bonazza S, Federico A, Formaglio F, Giusti 
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EM, Manzoni; Italian Consensus Conference on Pain in 
Neurorehabilitation, ICCPN, 2016) 
Anesthesiological procedures can be helpful in diagnosis (Polati 
E, Luzzani A, Schweiger V, Finco G, Ischia S., 2008; Ischia 
S, Polati E, Finco G, Gottin L. 2002; Ambrosio F, Paoletti F, 
Savoia G, Amantea B, Arcuri E, Avogaro F, Barbati A, Beltrutti 
D, Branca L, Camaioni D, De Conno F, De Luca A, Di Massa 
A, Evangelista M, Finco G, Ischia S, Mattia C, Mascaro A, 
Mercadante S, Orlandini G, Palomba R, Pasetto A, Polati E, 
Raffaelli W, Varrassi G, Visentin M, Zucco E; SIAARTI., 2003; 
Verlato G, Polati E, Speranza G, Finco G, Gottin L, Ischia S., 
2001). 
The patient can appreciate that there may not be always a 
technological or invasive solution to the pain problem, such as 
the use of a nerve block, or a pill, so the patient must be willing 
to undergo psychological and behavioral evaluation. 
Many factors may contribute to the symptoms. Concomitant 
depression, impaired cortical function and chronic anxiety, may 
all be conditions, in which the patients use the language and 
behavior of pain, to communicate their distress and suffering. 
Sometimes, during acute pain, growth hormone levels 
significantly increased within minutes, and beta endorphin and 
prolactin were elevated proportionately with severity of injury. 
Cortisol was inversely correlated with injury severity, possibly 
reflecting impaired release from the adrenal cortex after very 
severe injury (Hetz, W., Kamp, H. D., Zimmermann, U., Von 
Bohlen, A., Wildt, L., and Schuettler, J. 1996). 
In the final analysis, pain is communicated as a behavior, for it 
is only by word, grimacing, posturing and other behavioral 
signals that we know another individual is in pain. 
Patients may acquire behavioral aspects of their pain problems 
in chronic diseases and in Palliative Care, and along with 
psychological and tissue-damaging problems. 
Thus, such patients are unlikely to respond to therapy directed 
primarily at the tissue-damaging aspects, but may well need the 
combined efforts of conventional therapy aimed at the 
degenerative disease, psychological support, pharmacological 
treatment, and some behavior modification in an attempt to 
restore normal function. 
Acute pain signals pass through the thalamus, and then on to the 
No aspect of our mental life is more important to the quality and 
meaning of our existence than emotions. In view of the 
proliferation of increasingly fruitful exchanges between 
researches of different stripes, it is no longer useful to speak of 
the philosophy of emotion in isolation from the approaches of 
other disciplines, particularly psychology and neurology (De 
Sousa, 1987).  
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Emotions make certain features of situations or arguments more 
prominent, giving them a weight in our experience that they 
would have lacked in the absence of emotion (De Sousa, 1987; 
Roberts, 1988). 
Pain is considered to be chronic if it has remained essentially 
unrelieved for 6 months or longer. Chronic pain can be of many 
types and locations, and may or may not have specific tissue 
damage associated with it.  
Chronic pain travels through the hypothalamus, which is 
connected to the limbic system where emotional functioning 
(emotions or problems, such as anxiety or depression) seems to 
originate. In chronic pain there is a relationship between 
emotions, psychological state and the intensity of the pain 
experience. A variety of methods are available to help the Acute 
and Chronic Pain patient manage their depression, anxiety and 
stress level, including relaxation techniques and hypnosis. 
Usually, some combinations of these with therapies are applied 
for the best results. 
Knowing factors that aggravate or relieve pain helps clinicians 
to design a pain treatment plan in severe chronic illnesses. The 
initial pain assessment should elicit information about changes 
in activities of daily living, including work and recreational 
activities, sleep patterns, mobility, appetite, sexual functioning, 
and mood. 
A psychosocial assessment should emphasize the effect of pain 
on patients and their families, as well as patients' preferences 
among pain management methods. Patients who are able to 
answer should be asked about the effectiveness of past and 
present pain treatments, such as antineoplastic therapy or 
specific pharmacologic and nonpharmacologic therapies. 
Pain can be verified objectively, and interpretation of nervous 
system aberrations reveals individual differences in severe 
chronic diseases and in Palliative Care. If the feeling of 
objective existence is interpreted as a negative emotion, this 
phenomenon can lead to the formation of somatic symptoms. 
However, we must organize an accurate diagnosis to verify the 
nature of the pain in severe chronic diseases: if it is only 
physical or there is a psychosomatic amount. 
The number of people in their last years of life with 
advanced chronic conditions, palliative care needs and limited 
life prognosis due to different causes including multi-morbidity, 
organ failure, frailty and cancer is rising.  
The response to their needs is usually late and largely based 
around institutional palliative care focused on cancer. There is a 
great need to identify these patients, and integrate an 
early palliative psychosocial approach according to their 
individual needs in all settings, as suggested by the World 
Health Organization (WHO) (Gómez-Batiste X, Murray 
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S, Thomas K, Blay C, Boyd K, Moine S, Gignon M, den 
Eynden BV, Leysen B, Wens J, Engels Y, Dees M, Costantini 
M., 2016). 
To calm fears and anxiety in chronic pain, additional medicines 
– “adjuvants” – should be used; to calm fears and anxiety, 
additional non-pharmacological therapies and psychological 
therapies – “adjuvants” – should be used.  
In such cases, a variety of strategies can be implemented to 
improve the pain control and balance between analgesia and side 
effects (Vielhaber and Portenoy 2002).  
In 2002, NIH (National Institutes of Health) institutes, centers, 
and offices plus the Agency for Healthcare Research and 
Quality asked the Institute of Medicine to convene a study 
committee to explore scientific, policy, and practice questions 
that arise from the significant and increasing use of CAM 
(complementary and alternative medicine) therapies in severe 
chronic illnesses.  
Descriptive definitions of CAM include one by Ernst et al. 
(1995), who write that CAM is a “diagnosis, treatment and/or 
prevention which complements mainstream medicine by 
contributing to a common whole, satisfying a demand not met 
by orthodox, or diversifying the conceptual framework of 
medicine.” 
One of the most widely used classification structures, developed 
by NCCAM (2000), divides CAM modalities into five 
categories: 
1) Alternative medical systems, 
2) Mind-body interventions, 
3) Biologically based treatments, 
4) Manipulative and body-based methods, and 
5) Energy therapies. 
 
Anxiety and psychosomatic disorders in severe chronic 
diseases and in palliative care 
 
In cancer and severe chronic illnesses, we can have pain related 
to stress, anxiety and psychosomatic symptoms. 
Psychosomatic disorder is a condition in which psychological 
stresses adversely affect physiological (somatic) functioning to 
the point of distress. It is a condition of dysfunction or structural 
damage in bodily organs through inappropriate activation of the 
involuntary nervous system and the biochemical response 
(Levenson, JL., 2006, Sarno, J., 2006).  
In this context, this review will consider anxiety disorders from 
the perspective of the psychobiological mechanisms of 
vulnerability to extreme stress in severe chronic illnesses. 
Psychosomatic medicine is a field of behavioral medicine and a 
part of the practice of consultation-liaison psychiatry. 
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Psychosomatic medicine in palliative care, integrates 
interdisciplinary evaluation and management involving diverse 
clinical specialties including psychosocial oncology, psychiatry, 
psychology, neurology, internal medicine, surgery, allergy, 
dermatology and psychoneuroimmunology.  
Clinical conditions where mental processes act as a major factor 
affecting medical outcomes are areas where psychosomatic 
medicine has competence (Levenson, JL., 2006; Sarno, J., 
2006).  
Thus, the psychosomatic symptom emerges as a physiological 
concomitant of an emotional state. In a state of rage or fear, for 
example, the stressed person’s blood pressure is likely to be 
elevated and his pulse and respiratory rate to be increased. When 
the fear passes, the heightened physiologic processes usually 
subside. If the person has a persistent inhibited fear (chronic 
anxiety), however, which he is unable to express overtly, the 
emotional state remains unchanged, though unexpressed in the 
overt behavior, and the physiological symptoms associated with 
the anxiety state persist. With time, such a person becomes 
aware of the physiological dysfunction (Sarno, J., 2006; Fink, 
G., 2011). 
Clinical neurobiological research pertaining to these anxiety 
disorders has been dominated by investigations directed toward 
identifying dysfunctional neural circuits and neurochemical 
systems, vulnerability genes, and psychopharmacology. Very 
often, he develops concern over the resulting physical signs and 
symptoms, but he denies or is unaware of the emotions that have 
evoked the symptoms ((Levenson, JL., 2006; Sarno, J., 2006; 
Fink, G., 2011).  
Some physical symptoms in severe chronic diseases are believed 
to have a psychological component derived from the stresses 
and strains of everyday living. This has been suggested, for 
example, of muscular pain, tension type headache or high blood 
pressure, which some researchers have suggested may be related 
to stresses in everyday life (Sarno, J., 2006). 
However, within a psychosomatic framework, mental and 
emotional states are seen as capable of significantly influencing 
the course of any physical illness. Psychiatry traditionally 
distinguishes between psychosomatic disorders, disorders in 
which mental factors play a significant role in the development, 
expression, or resolution of a physical illness, and somatoform 
disorders, disorders in which mental factors are the sole cause of 
a physical illness. 
It is difficult to establish whether an illness has a psychosomatic 
component. A psychosomatic component is often inferred when 
there are some aspects of the patient's presentation that are 
unaccounted for by biological factors, or some cases where there 
is no biological explanation at all. For instance, Helicobacter 
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pylori causes 80% of peptic ulcers. However, most people living 
with Helicobacter pylori do not develop ulcers, and 20% of 
patients with ulcers have no H. pylori infection. Therefore, in 
these cases, psychological factors could still play some role 
(Fink, G., 2011). Similarly, in irritable bowel syndrome, there 
are abnormalities in the behavior of the gut. However, there are 
no actual structural changes in the gut, so stress and emotions 
might still play a role (Melmed, Raphael N., 2001).  
The strongest perspective on psychosomatic disorders is that 
attempting to distinguish between purely physical and mixed 
psychosomatic disorders is increasingly obsolete as almost all-
physical illness have mental factors that determine their onset, 
presentation, maintenance, susceptibility to treatment, and 
resolution (Charney DS., Barlow DH., Botteron K., et al., 2002; 
McNally RJ., 2002). 
According to this view, even the course of serious illnesses, such 
as chronic severe diseases and cancer, can potentially be 
influenced by a person's thoughts, feelings, emotions and 
general states of mental suffering and physical symptoms. 
Addressing such factors is the concern of the applied field 
of behavioral medicine. In modern society, psychosomatic 
aspects of illness are often attributed to stress (Treasaden,IH., 
Basant K. Puri, Laking PJ., 2002), making the cure of stress one 
important factor in the development, treatment, and prevention 
of psychosomatic illness. 
In the field of psychosomatic medicine, the phrase 
"psychosomatic illness" is used more narrowly than it is within 
the general population. In contrast, in contemporary 
psychosomatic medicine, the term is normally restricted to those 
illnesses that do have a clear physical basis, but where it is 
believed that psychological and mental factors also play a role. 
Some researchers within the field believe that this overly broad 
interpretation of the term may have caused the discipline to fall 
into disrepute clinically (Greco, M., 1998).   
For this reason, among others, the field of behavioral medicine 
has taken over much of the remit of psychosomatic medicine in 
practice and there exist large areas of overlap in the scientific 
researches (Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, 
Guthrie D, Fahey JL, Morton DL.1993; Spiegel, D, Bloom,JR, 
Kraemer, HC, Gottheil, E., 1989; Coyne JC, Stefanek M, Palmer 
SC, 2007; Wise, Thomas N., 2008; ).  
The anxiety disorders in severe chronic illnesses, including 
panic disorder, generalized anxiety disorder, social anxiety 
disorder, psychosomatic symptoms and posttraumatic stress 
disorder, are among the disabling psychological disorders in 
palliative care (Brugnoli MP., Brugnoli A., Norsa A., 2006; 
Brugnoli MP., 2014a, 2014b; Asaad, Ghazi, 1996; Erwin, E, 
2002) 
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These disorders are currently diagnosed using standardized 
diagnostic criteria (Diagnostic and Statistical Manual of Mental 
Disorders [DSM-5] (American Psychiatric Association, 2013) 
and International Classification of Diseases [ICD-10]) (ICD-10-
WHO Version for 2016), which are almost exclusively based 
upon phenomenology, and not genetics, etiology, or 
pathophysiology. 
Anxiety disorders and mood disorders commonly produce 
physical symptoms. Clinicians need to rule out somatic 
symptoms due another primary psychiatric condition before 
considering a somatic symptom disorder diagnosis. Somatic 
symptoms can dramatically improve with successful treatment 
of the anxiety or mood disorder. 
The DSM-5 includes 5 specific diagnoses in the Somatic 
Symptom Disorder and Other Related Disorder category 
(American Psychiatric Association, 2013). Specific Somatic 
Symptom Disorders diagnoses include: 
(1) Somatic symptom disorder;  
(2) Conversion disorder;  
(3) Psychological factors affecting a 
medical condition;  
(4) Factitious disorder;  
(5) Other specific and nonspecific 
somatic symptom disorders (Yates WR., 
Dunayevich, E., 2016). 
Some evidence exists that somatization disorder is associated 
with increased risk for suicide attempts (Treasaden, IH., Basant 
K. Puri, Laking PJ., 2002).  Patients with somatic symptom 
disorders may be misdiagnosed (Yates WR., Dunayevich, E., 
2016; Chioqueta AP, Stiles TC., 2004). 
Somatic symptom disorders in severe chronic illnesses may 
existing in childhood, adolescence, early adulthood or older 
adults. New onset of unexplained somatic symptom disorders, in 
chronic illnesses, should evidence of major depression and 
anxiety associated with somatization (Brugnoli MP., Brugnoli 
A., Norsa A., 2006; Yates WR., Dunayevich, E., 2016). 
Most neuro-biochemical changes associated with pain and stress 
are a result of stimulation of the sympathetic nervous system, 
specifically the fight-or-flight response: in acute stress, this 
response triggers the release of substances: catecholamines, 
which include epinephrine, norepinephrine and cortisol, from 
the adrenal glands. These substances prepare the body to react to 
immediate danger by increasing heart rate, 
increasing oxygen delivery to the brain, dilating blood vessels in 
skeletal muscles, and increasing blood glucose levels (Charney 
DS., 2003; Rapee RM., 2000; Prior M., Smart D., Sanson A., 
Oberklaid F., 2000; Vasey MW., Dadds MR., 2001; Kagan J., 
Snidman N., 1999; Krizanova O, Babula P, Pacak K., 2016). 
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Chronic stress is characterized by the persistent presence of 
sources of frustration or anxiety that a person encounters every 
day in the severe chronic diseases.  
Psychosomatic disorders resulting from chronic stress may 
include pain, anxiety, hypertension, respiratory failure, 
gastrointestinal disturbances, migraine and tension headaches, 
dermatitis, fibromyalgia and ulcers (Krizanova O, Babula P, 
Pacak K., 2016). 
Pain and anxiety are the most frequent stress-response’ problems 
in palliative care. 
The patient’s pain and anxiety should be acknowledged as a real 
physiological existent problem with biochemical changes for the 
patient. Attempts to differentiate between “real” and “unreal” 
pain, “organic” and “psychosomatic” are usually fruitless and 
only succeed in challenging such patients to attempt to prove 
further the “reality” of their suffering. The patient can appreciate 
that there may not be just a technological or pharmacological 
solution to his problem, such as the use of a nerve blocks, or 
medicines, so the patient must be willing to undergo 
psychological and behavioral evaluation. Many factors may 
contribute to the symptoms. Trauma, serious illnesses, 
concomitant depression, impaired cortical function and chronic 
anxiety, may all be conditions in which the patients use the 
language and behavior of pain to communicate their distress.  
In chronic stress, continuous stimulation of the fight-or-flight 
response leads to constant production and secretion of 
catecholamines. This has a variety of physiological concerns, 
including hyperglycemia, which can lead to type II diabetes 
mellitus, and hypertension, which can lead to cardiovascular 
diseases. Because some catecholamines such as norepinephrine 
act as neurotransmitters in the brain, these substances can 
modify cognition and other mental processes, leading to poor 
concentration, mood swings, agitation, depression, and anxiety 
(Steckler T, Holsboer F., 1999; Strome EM, Wheler GH, Higley 
JD, Loriaux DL, Suomi SJ, Doudet DJ., 2002; Antonijevic IA, 
Murck H, Bohlhalter S, Frieboes RM, Holsboer F, Steiger A., 
2000; Bale TL, Vale WW., 2003). 
In addition, long-term stress-induced cortisol secretion from the 
adrenal glands can reduce immune function, leading to increased 
risk of illness (Charney DS., 2003; Krizanova O, Babula P, 
Pacak K., 2016). 
How the motor, cognitive, and affective areas of the cerebral 
cortex influence the adrenal medulla in severe chronic diseases? 
How and where does the “mind” (brain) influence the “body” 
(internal organs and their functions)?  
Recent studies identified key areas in the primate cerebral cortex 
that are linked through multisynaptic connections to the adrenal 
medulla. The most substantial influence originates from a broad 
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network of motor areas that are involved in all aspects of 
skeletomotor control from response selection to motor 
preparation and movement execution (Allen YS, Adrian TE, 
Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM., 1983; 
Heisler L., Chu HM., Brennan T., et al., 1998; Parks C., 
Robinson P. ibille E, Shenk T, Toth M., 1998; Gross C., Zhuang 
X., Stark K., et al., 2002; Drevets WC., Frank JC., Kupfer DJ., 
et al., 1999; Gingrich JA., 2002; Holmes A., Yang RJ., Murphy 
DL., Crawley JN., 2002; Caspi A., Sugden K., Moffit TE., et al., 
2003). 
Thus, cortical areas involved in the control of movement, 
cognition, and affect are potential sources of central commands 
to influence sympathetic arousal. These results provide an 
anatomical basis for psychosomatic illness in chronic pain and 
anxiety, where mental states can alter the organ functions (Dum 
RP, Levinthal DJ, Strick PL., 2016). 
These studies and results have a number of important functional 
implications. First, they emphasize the importance of the cortical 
motor areas in the top-down influence over the adrenal medulla 
during stress and psychosomatic disorders. Normal limb and 
body movements are accompanied by coordinated changes in 
sympathetic output that are proportional to the metabolic 
demands of the task (Dum RP, Levinthal DJ, Strick PL., 2016).  
An important component of the sympathetic activity is thought 
to be due to a “central command” that can precede any change in 
muscle activity, and w can have fibromialgic syndromes in 
severe chronic illnesses (Dum RP, Levinthal DJ, Strick PL., 
2016; Cechetto DF, Saper CB., 1990; Williamson JW, Fadel PJ, 
Mitchell JH., 2006; Shoemaker JK, Wong SW, Cechetto DF., 
2012). 
This command is a “predictive” response because it prepares the 
body to meet the anticipated metabolic needs of activities like 
exercise, emotional states, and fight or flight. Scientific 
researchers suggest that the central commands to prepare for and 
generate visceromotor output originate from the same cortical 
areas that are involved in the preparation and generation of 
skeletomotor output (Dum RP, Levinthal DJ, Strick PL., 2016; 
Shoemaker JK, Wong SW, Cechetto DF., 2012; Hatanaka N, 
Nambu A, Yamashita A, Takada M, Tokuno H., 2001; Strack 
AM, Sawyer WB, Platt KB, Loewy AD., 1989). 
Second, they found that the top-down influence over the adrenal 
medulla by M1 originates largely from its trunk representation. 
This region of M1 projects to thoracic segments of the spinal 
cord (Dum RP, Levinthal DJ, Strick PL., 2016; Shoemaker JK, 
Wong SW, Cechetto DF., 2012; Hatanaka N, Nambu A, 
Yamashita A, Takada M, Tokuno H., 2001).  
These observations suggest that there is a link between the 
descending control of “core muscles” and the regulation of 
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sympathetic output in chronic pain and anxiety (Innes KE, 
Bourguignon C, Taylor AG., 2005; Varga K, Kekecs Z., 2014; 
Astin JA, Shapiro SL, Eisenberg DM, Forys KL., 2003; Searle, 
J., 1990; Tononi G, Koch C., 2008; Tononi G, Koch C., 2015).            
In many patients with anxiety disorders, especially those with 
severe chronic illnesses fear conditioning causes vivid recall of 
memories of traumatic events and autonomic hyperactive 
arousal (Dum RP, Levinthal DJ, Strick PL., 2016)  
Fear conditioning is conceptualized as a form of associative 
learning in which subjects come to express fear responses to 
neutral conditioned stimuli (CS), which are paired with aversive 
unconditioned stimuli (US) (Dum RP, Levinthal DJ, Strick PL., 
2016). Because of this pairing, the CS acquire the ability to elicit 
a spectrum of behavioral, autonomic, and endocrine responses 
that normally would only occur in the context of danger. Fear 
conditioning can be adaptive and enable efficient behavior in 
situations like severe chronic diseases.  
The long loop pathway indicates that sensory information 
relayed to the amygdala undergoes substantial higher level 
processing, thereby enabling assignment of significance, based 
upon prior experience of anxiety, to complex stimuli (Dum 
RP, Levinthal DJ, Strick PL.2016; Blair HT, Schafe GE, Bauer 
EP, Rodrigues SM, LeDoux JE., 2001; Walker DL, Davis M., 
2000; Grillon C., 2002; Bauer EP, Schafe GE, LeDoux JE., 
2002). 
This link could provide a neural substrate for the control of 
stress and psychosomatic disorders through “core” and mind-
body therapies and exercises, such as relaxation, verbal 
suggestions and visual imagery, yoga, acupuncture, mindfulness, 
autogenic training, hypnosis and self-hypnosis (Brugnoli MP, 
2014a; Barber TX., Spanos NP., Chaves JF., 1974; Frischholz 
EJ., 2013; Gansler T., Kaw C., Crammer C., Smith T., 2008; 
Gelfman LP., Meier DE., Morrison RS., 2008; Grinder J., 
Bandler R., 1976; Hammond DC., 2010; Kleinbub JR, Palmieri 
A, Broggio A, Pagnini F, Benelli E, Sambin M, Sorarù G., 2015; 
Lankton S. , 2013; Lazar S.W., Bush G., Gollub R. L., 
Fricchione G. L., Khalsa G., Benson H. , 2000; Lotfi-Jam K., 
Carey M., Jefford M., Schofield P., Charleson C., Aranda S., 
2008; Marchioro G., Azzarello G., Viviani F., Barbato F., 
Pavanetto M., Rosetti F., Pappagallo GL., Vinante O., 2000; 
Perez-De-Albeniz A., Holmes J., 2000; Plaskota M., Lucas C., 
Evans R., Cook K., Pizzoferro K., Saini T., 2012; Raz A., 2011; 
Richardson J., Smith JE., McCall G., Richardson A., Pilkington 
K., Kirsch I., 2007; Robertson D., 2012; Sepúlveda C., Marlin 
A.,Yoshida T., Ullrich A., 2002; Shiber JR., Santana J. , 2006; 
Temel J.S., et al.,, 2010; Udo I., Gash A. , 2012; Untas A., 
Chauveau P., Dupré-Goudable C., Kolko A., Lakdja F., 
Cazenave N., 2013; Yapko MD., 2013; Wonderling, D., 2006; 
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Zitman FG, van Dyck R, Spinhoven P, Linssen AC., 1992; 
Kekecs Z, Varga K., 2013; Ronel J, Mehilli J, Ladwig KH, 
Blättler H, Oversohl N, Byrne RA, Bauer A, Schneider S, Linde 
K, Henningsen P, Lahmann C, Noll-Hussong M, Meissner K., 
2011; Häuser W, Hagl M, Schmierer A, Hansen E., 2016; 
Lauche R, Cramer H, Häuser W, Dobos G, Langhorst J., 2015; 
Anbar RD., 2008; Anbar RD., Linden JH., 2010). 
In addition, the sympathetic system innervates structures of the 
head (eye, salivary glands, mucus membranes of the nasal 
cavity), thoracic viscera (heart, lungs) and viscera of the 
abdominal and pelvic cavities (eg, stomach, intestines, pancreas, 
spleen, adrenal medulla, urinary bladder) (McCorry LK., 2007; 
Fox SI., 2006; Guyton AC, Hall JE., 2006; Hoffman BB., 2001; 
Hoffman BB, 2001a; Iversen S, Iversen L, Saper C., 2000). 
The parasympathetic system predominates during quiet, resting 
conditions and it can be overstimulated during chronic stress and 
anxiety. The preganglionic neurons that arise from the brainstem 
exit the CNS through the cranial nerves.  
Therefore, the effects of the parasympathetic system tend to be 
more discrete and localized, with only specific tissues being 
stimulated at any given moment, compared to the sympathetic 
system where a more diffuse discharge is possible (McCorry 
LK., 2007; Fox SI., 2006; Guyton AC, Hall JE., 2006; Hoffman 
BB., 2001; Hoffman BB., 2001a; Iversen S, Iversen L, Saper C., 
2000; Dosenbach NUF, Fair DA, Cohen AL, Schlaggar BL, 
Petersen SE., 2008). 
During acute and chronic pain, stress and anxiety, the loss of 
homeostasis between sympathetic and parasympathetic system, 
generates the psychosomatic symptoms and disorders. 
Somatization is defined as the tendency to experience 
psychological distress in the form of physical symptoms. 
The psychosomatic symptoms are described and classify in the 
International Statistical Classification of Diseases and Related 
Health Problems 10th Revision (ICD-10-WHO Version for 
2016, Chapter V). 
In severe chronic illnesses, anxiety and psychosomatic 
symptoms are usually of two types, neither of which indicates a 
physical disorder of the organ or system concerned. First, there 
are complaints based upon objective signs of autonomic arousal, 
such as palpitations, sweating, flushing, tremor, and expression 
of fear and distress about the possibility of a physical disorder. 
Second, there are subjective complaints of a nonspecific or 
changing nature such as fleeting aches and pains, sensations of 
burning, heaviness, tightness, and feelings of being bloated or 
distended, which are referred by the patient to a specific organ 
or system: 
- Cardiac neurosis 
- Gastric neurosis 
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- Neurocirculatory asthenia 
Psychogenic forms of: 
- aerophagy 
- cough 
- diarrhoea 
- dyspepsia 
- dysuria 
- flatulence 
- hiccough 
- hyperventilation 
- increased frequency of micturition 
- irritable bowel syndrome 
- pylorospasm 
- backache 
- headache 
- Somatoform pain disorder 
- Nonorganic sleep disorders 
- Undifferentiated somatoform disorder 
- Somatization disorder 
- Unspecified somatoform disorder 
- Conversion disorder 
- Hypochondriasis 
- Body dysmorphic disorder 
- Pain disorder 
The symptoms included here are the presence of an excruciating 
pain in one or more various parts of the body. Psychosomatic 
chronic symptoms in palliative care, pain and anxiety behaviors 
are cognitively impaired; they are communicated by:  
(a) Facial expression:  
                                     i. Slight frown, frightened face  
                                     ii. Rapid blinking  
(b) Verbalizations, vocalizations: 
                                     i. Verbally abusive  
                                     i. Calling out, chanting, grunting  
(c) Body movements:  
i. Rigid, tense  
ii. Fidgeting  
iii. Increased pacing, rocking  
(d) Changes in interpersonal interactions:  
i. Aggressive, combative, resisting care  
ii. Decreased cultural interaction  
iii. Socially inappropriate, disruptive  
(e) Changes in activity patterns or routines:  
i. Refusing food  
ii. Increased rest periods  
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iii. Sleep pattern changes  
(f) Mental status changes:  
i. Crying, tears  
ii. Increased confusion  
iii. Irritable 
In Palliative Care, is important to pay attention to evaluate 
always these signs and indicators to better relief anxiety and 
suffering (Brugnoli MP, 2014a, 2014b; Krizanova O, Babula P, 
Pacak K., 2016; Vasey MW., Dadds MR., 2001). 
It is essential understanding if we have anxiety and 
psychosomatic symptoms associated to the severe chronic 
illness. 
The psychosomatic symptoms cause one or more psychological 
and bodily-related symptoms, including pain. Even if the patient 
has a concomitant severe chronic disease, the symptoms may or 
may not be associated to the physical illness. However, 
regardless, they cause excessive and disproportionate levels of 
distress and a problematic quality of life.  All symptoms are, by 
definition, subjective, and all disease occurs in, and is influenced 
by, a psychosocial context. 
The chronic anxiety and psychosomatic symptoms, in palliative 
care, can involve and increase one or more different symptoms 
in organs and body systems, such as: 
 Pain 
 Anxiety  
 Gastrointestinal complaints 
 Urogenital symptoms 
 Respiratory distress 
 Cardiovascular symptoms 
 Fibromyalgia  
 Dermatological symptoms 
Many people who have psychosomatic disorders in Palliative 
Care, will also have anxiety disorders. The distress patients 
experience from pain and other problems are real, regardless of 
whether or not a physical explanation can be found. The distress 
from symptoms significantly affects daily functioning, 
increasing the disability associated with their severe chronic 
illness. When there is a medical condition causing their 
symptoms, they may not recognize that the amount of distress 
they are experiencing or displaying is excessive. Patients may 
also dismiss any suggestion that psychiatric factors are playing a 
role in their symptoms. 
We need to consider as psychosomatic symptom, the medical 
conditions that cause vague and diffuse signs. In addition, 
consider somatization as part of a mood for anxiety or chronic 
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stress’ disorder in palliative care (Levenson, James L., 2006; 
Melmed, Raphael N., 2001). 
Psychosomatic disorders may affect almost any part of the body, 
though they are usually found in systems not under voluntary 
control(Levenson, James L., 2006; Taunton OD, Roth J, Pastan 
I., 1969; Kulpa M, Ziętalewicz U, Kosowicz M, Stypuła-Ciuba 
B, Ziółkowska P., 2016; Park S, Hong JP, Lee JK, Park YM, 
Park Y, Jeon J, Ahn MH, Yoon SC., 2016; Choi KH, Park SM., 
2016). 
Commonly, we have to consider that the physical psychosomatic 
symptoms to threat:  
 are correlates of stress and anxiety,  
 may maintain stress and anxiety,  
 are supported by an interplay of automatic (bottom-up) 
and controlled (goal-directed, top-down) processes. 
In severe chronic illnesses with chronic anxiety and 
psychosomatic symptoms, we use psychological interventions as 
psychotherapy or clinical hypnosis (Fanmin Zeng, Xueli Sun, 
Bangxiang Yang, Hong Shen, Ling Liu, 2016).  
The psychological treatment of pain, anxiety and related 
psychosomatic symptoms in severe chronic diseases and in 
Palliative Care 
 
Treatment of psychosomatic symptoms in palliative care is 
difficult. It responds best to a psychologically oriented physician 
who is able and willing to take final responsibility and therapy 
for both physical and psychological care. 
A strong doctor-patient relationship is key to getting help with 
psychosomatic symptoms. Seeing a single health care provider 
with experience managing symptoms can help cut down on 
unnecessary tests and treatments. The focus of treatment is on 
improving daily functioning, not on managing symptoms. Stress 
reduction is often an important part of getting better. Working in 
a multidisciplinary team should be the best way to cure the 
psychosomatic disorders in palliative care. 
Cognitive symptoms can be alleviated with cognitive-behavioral 
therapy, and biological symptoms can be alleviated by 
medicines and local and systemic physical treatment.  
It is worth noting that the methods intended to increase the 
knowledge of bodily symptoms from additional perspectives 
should vary from patient to patient and implement a diverse 
mode of thinking (Fanmin Zeng, Xueli Sun, Bangxiang Yang, 
Hong Shen, Ling Liu, 2016; Brown RJ., 2004;  Fink P., 1966; 
Fava GA, Sonino N., 2000; Kroenke K, Spitzer RL, Williams 
JBW., 2002; Katon W, Kleinman A, Rosen G., 1982). 
There have been few, if any, reported cures of this chronic 
condition. The therapeutic goal is to minimize unnecessary and 
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often deleterious medical interventions and to maximize the 
patient's quality of life. The patient is likely to continue to seek 
medical care from new providers unless enrolled in an ironclad 
system that prevents this behavior, and she is unlikely to accept 
a psychological explanation for her difficulties. It is sometimes 
possible to effect a successful referral to a mental health 
professional by emphasizing the emotional toll the disabilities 
are taking on the patient and the role of the mental health 
professional as an adjunct to the primary care provider 
(Fillingim RB, Bruehl S, Dworkin RH, Dworkin SF, Loeser JD 
et Al., 2014; Kroenke K, Rosmalen JG., 2006; Kirmayer LJ, 
Robbins JM., 1991; IASP Classification of Chronic Pain).  
Understanding the pathophysiology of the psychosomatic 
symptoms in palliative care, aids in selection of treatment plans 
for correcting the negative effects of the psyche on specific body 
conditions. We know that the pharmachological options include 
standard opioids in cancer and other painkillers, psychotropic 
medications, alternative herbs and supplements. However, 
adjuvant other options include psychotherapies, biofeedback, 
cognitive-behavioral methods, hypnosis, meditation, progressive 
relaxation, acupuncture and many different types of holistic 
approaches (Shenefelt PD., 2010).   
In addition to the pharmacological therapy used in any organ 
symptom and disease for other somatoform disorders, it is 
important to avoid addicting the patient to analgesics when it is 
possible, considering that in cancer very often patients need 
opioids for a complete pain relief. This concern should never 
deter physicians from providing adequate analgesia to acutely ill 
or patients at the end of life. There is a great deal of empirical 
evidence that such patients are widely denied appropriate pain 
relief. When in cancer the pain is improved by a psychosomatic 
problem, generally the single pharmacological therapy does not 
work, even if we use a high dosage of medicines and opioids. 
Pain clinics and departments, can be very useful in helping 
chronic pain patients to reduce the use of pharmacologic agents 
with adjuvant psychological and spiritual approaches that 
improve the quality of lives and give to the patient a better 
control of the pain (Bhatnagar S, Gupta M., 2016). 
In palliative care, we have to consider that most cancer pain is 
caused by the tumor pressing on bones, nerves or other organs in 
the body. Sometimes pain is related to the cancer treatment:  
some chemotherapy drugs can cause neuropathic pain as 
numbness and tingling in the hands and feet or a burning 
sensation at the place where they are injected. Radiotherapy can 
cause skin redness and irritation. However, some pain may have 
nothing to do with the cancer. 
Many patients suffering from pain and psychosomatic diseases 
associated to the chronic severe diseases, have a good response 
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to a combination of multicomponent adjuvant treatments, 
psychotherapies, and hypnosis. In less severe cases, patients can 
learn to manage stress without drugs, for example with self-
hypnosis (Hök J, Tishelman C, Ploner A, Forss A, Falkenberg 
T., 2008; Brugnoli MP, 2014). 
The Psychosocial and Psychological interventions, consist of a 
variety of therapies related to the very different symptoms. 
 
Clinical Hypnosis and self-hypnosis for pain, anxiety and 
psychosomatic symptom relief in severe chronic diseases and 
in Palliative care 
 
Specific objectives and hypotheses 
Hypnosis has many useful psychosomatic applications in pain 
and anxiety relief in severe chronic diseases. Medical 
hypnotherapy involves guiding the patient into a trance state of 
narrowed awareness, focused attention, selective wakefulness, 
and heightened suggestibility for a specific purpose such as 
relaxation, pain reduction, or habit modification. The hypnotic 
trance compared with the usual waking state has objectively 
documented differences in regional cerebral blood flow 
(Rainville P, Hofbauer RK, Bushnell MC, et al., 2002) and EEG 
(Freeman R, Barabasz A, Barabasz M, Warner D., 2000) 
patterns. One way that hypnosis may make suggestions more 
effective is by inhibiting competing thoughts so that the focus 
can be solely on the suggestion (Barrios AA., 2009). Hypnosis 
may improve or clear numerous psychosomatic disorders 
(Brugnoli MP, 2014a; Shenefelt PD., 2008; Willemsen R, 
Vanderlinden J, Deconinck A, Roseeuw D., 2006). 
Hypnosis is a therapeutic technique in which clinicians make 
suggestions to individuals who have undergone a procedure 
designed to relax them and focus their minds. Although 
hypnosis has been controversial, most clinicians now agree it 
can be a powerful, effective therapeutic technique for a wide 
range of conditions, including pain, anxiety and mood disorders 
(APA Division 30). 
Clinical hypnosis in Pain Therapy and Palliative Care refers to 
the conscious calm awareness of cognitions, sensations, 
emotions and experiences. 
The stages of hypnosis used in severe chronic illnesses and 
palliative care, are frequently achieved also through mindfulness 
and meditative states, which are practices that cultivate non 
judgmental awareness of the present moment. 
Clinical hypnosis in palliative care, derives from as a mental 
factor it signifies presence of mind, attentiveness to the present, 
rather than the faculty of memory regarding the past. It has the 
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characteristic of not wobbling, not floating away from the 
object. Its function is absence of confusion or non-forgetfulness 
(Brugnoli MP, 2014; Montgomery et al., 2007, 2010; Liossi C, 
Hatira P., 1999). 
It is manifested as guardianship, or as the state of confronting an 
objective field. Its proximate cause is strong perception, and 
inner awareness. 
Hypnosis is defined as an agreement between a person 
designated as the health-care hypnotist and a person designated 
as the patient to participate in a psychotherapeutic technique in 
which the hypnotist provides suggestions for changes in 
sensation, perception, cognition, affect, mood, or behavior 
(Montgomery et al., 2007, 2010). Hypnosis has documented 
efficacy in a variety of conditions such as mental health 
disorders, smoking cessation, obesity, pain reduction, anxiety, 
and nausea and vomiting (Deng et al., 2009; Elkins et al., 2004, 
2008, 2010; Monti D et Al, 2006, 2007, 2008; Lang Elvira V, 
Berbaum Kevin S, Pauker Stephen G, Faintuch Salomao, 
Salazar Gloria M, Lutgendorf Susan, Laser Eleanor, Logan 
Henrietta, Spiegel David., 2008).  
Optimal results are achieved by a trained therapist who has 
developed a good rapport and a strong level of trust with the 
patient. A comfortable environment, free of distraction, is 
needed, and the patient must be willing to undergo the procedure 
(Cassileth et al., 2007). 
The neural correlates of Clinical Hypnosis  
Mind-body interventions (MB), s clinical hypnosis, are practices 
that focus on the interactions among the brain, body, mind, and 
behavior, with the intent of using the mind to alter physical 
function and promote overall health (Elkins, Fisher, & Johnson, 
2010). Mind-body approaches should be part of a 
multidisciplinary approach and aimed at reducing anxiety, mood 
disturbance, pain and improving QOL (Deng et al., 2009). 
Understandably, a diagnosis of cancer can generate feelings of 
helplessness and hopelessness and is associated with a myriad of 
psychosocial difficulties. Understanding and assisting patients 
with appropriate MB interventions can enhance the provider-
patient relationship, improve symptoms, and enable patients to 
assign meaning to their experience. 
Hypnotic treatment in severe chronic diseases, for pain and 
symptoms relief, has proven efficacy as adjuvant therapy, and 
should be offered to any individual, who expresses an interest in 
this method. While some theorize hypnotizability as a changing 
attribute of the individual, there is a growing body of literature 
that indicates hypnotizability may be characterized as a 
constellation of potentially modifiable attitudes and skills, which 
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are strongly influenced by related factors, as suffering, in severe 
chronic diseases. 
Consciousness has many aspects. These include awareness of 
the world, feelings of control over one's behaviour and mental 
state (volition), and the notion of continuing self. Focal 
(executive) attention is used to control details of our awareness 
and is thus closely related to volition. 
The problem of consciousness involves many difficult and 
overlapping issues (Block 1995; Posner 1994). Perhaps the most 
frequently discussed role of consciousness involves awareness 
of our sensory world. Another aspect of consciousness is the fact 
or illusion of voluntary control. In the course of development, a 
central issue is the awareness of one's self, and another is the 
form of voluntary control involved in self-regulation. These 
functions develop within the dyad involving the child and the 
caregiver as a carrier of the culture's socialization process. It is 
possible, even likely, that brain mechanisms subserving these 
various forms of consciousness may cut across definitions in 
ways that defy the usual logical and philosophical distinctions. 
Clinical Hypnosis research binds phenomenology and 
neuroscience (Lifshitz M, Cusumano EP, Raz A., 2013). 
Most researchers leverage bottom-up suppression to unlock the 
underlying mechanisms of unconscious processing. However, a 
top-down approach – for example via hypnotic suggestion – 
paves the road to experimental innovation and complementary 
data that afford new scientific insights concerning attention and 
the unconscious (Mathieu Landry, Krystèle Appourchaux, 
Amir Raz, 2014). 
Hypnosis selectively targets and modifies perception of sensory 
events. For example, it can modify the perception of the colors 
(Kosslyn et al., 2000; Mallard and Bryant, 2001; Spiegel, 
2003; McGeown et al., 2009; Kallio and Koivisto, 
2013; Koivisto et al., 2013; Mathieu Landry, Krystèle 
Appourchaux, Amir Raz, 2014), induce compelling experiences 
of grapheme -color synesthesia – a condition characterized by 
perceptual experiences of anomalous combinations of cross-
modal sensations (Cohen Kadosh et al., 2009; Anderson et al., 
2014), and even temporarily abolish co-occurrences of 
secondary sensory experiences in synesthetes (Terhune et al., 
2010).  
Indicating the reliability and sustainability of these remarkable 
changes, hypnotically induced alteration of color perception 
correlates with corresponding modifications in neural response 
(Kosslyn et al., 2000; McGeown et al., 2012). Specifically, 
neuroimaging results of hypnotically induced altered perception 
show modulation of brain regions associated with color 
processing – i.e., bilateral fusiform gyrus, primary visual area 
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(Kosslyn et al., 2000; McGeown et al., 2012; Mathieu Landry, 
Krystèle Appourchaux, Amir Raz, 2014).  
We can use this properties of hypnosis on perceptions, to 
modulate acute and chronic pain. 
Hypnotic suggestions allow researchers to generate and study 
atypical experiential states that would otherwise prove unstable, 
rare, or short-lived. One fruitful approach employs hypnotic 
suggestions to produce “virtual patients” with transient 
syndromes nearly identical to genuine clinical 
psychopathologies in terms of experiential substrates and in 
some cases also neurobiological correlates (Oakley and 
Halligan, 2009; Woody and Szechtman, 2011; Lifshitz M, 
Cusumano EP, Raz A., 2013). 
Clinical hypnosis offers insight into spontaneous cognition and 
the resting brain. Contemplative practices including hypnosis are 
emerging as valuable tools for investigating the default-mode—
a network of brain regions that show increased activity at rest. 
Default-mode network (DMN) activity correlates with a wide 
range of internally directed cognitive processes, including mind-
wandering, self-oriented thinking, moral reasoning, and episodic 
memory (Buckner et al., 2008); yet, it is difficult to 
experimentally manipulate the DMN alongside these processes 
because the defining feature of the DMN is that it activates 
spontaneously, in the absence of external task demands.  
Accordingly, in the past few years, researchers have begun 
employing contemplative practices in concert with intrinsic 
connectivity imaging methods to elucidate the psychological 
correlates of resting-state brain networks such as the DMN (e.g., 
McGeown et al., 2009; Brewer et al., 2011; Pyka et al., 2011; 
Hasenkamp et al., 2012; Pagnoni, 2012; Taylor et al., 2013). 
Following this approach, a recent study reported that hypnotic 
induction increased subjective ratings of attentional absorption 
and decreased ratings of mind-wandering.  
Moreover, these changes were associated with decreased DMN 
activity and increased activity in prefrontal attention networks 
(Deeley et al., 2012). Another recent account leveraged a similar 
neurophenomenological approach to show that subjective ratings 
of hypnotic depth following an induction were associated with 
changes in global functional connectivity in the 
electroencephalography signal. Furthermore, differences in 
subjective experiential dimensions such as “imagery,” 
“everyday concerns,” and “vestibular and other bodily 
experiences” were associated with distinct patterns of 
connectivity (Cardeña et al., 2013).  
These studies illustrate how manipulating the experiential state 
of the subject while collecting subjective reports can not only 
enrich and even guide the investigation of brain networks, but 
31 
 
also their psychological correlates in therapy (Lifshitz M, 
Cusumano EP, Raz A., 2013). 
Although hypnosis typically involves suggestions emphasizing 
specific, and often unusual, behaviors or perceptual experiences, 
as visualizations for pain and anxiety relief. 
The defining feature of hypnosis is the flexibility it affords for 
modulating aspects of consciousness, rather than one particular 
state of attention that it induces. Indeed, numerous cognitive and 
neuroimaging reports have documented the power suggestion 
wields over attention functions and associated brain networks 
(Egner et al., 2005; Raz et al., 2005; Iani et al., 2006, 2009; 
Priftis et al., 2011; Raz and Campbell, 2011; Terhune et 
al., 2011). Such potent subjective alterations could potentially be 
adapted to derail habitual patterns of conceptual judgment and 
support non-judgmental meta-awareness of the present moment. 
Investigators have already begun experimenting with using 
suggestion-based approaches to foster states of mindful meta-
awareness for therapeutic psychological purposes (Lynn et 
al., 2006, 2010). 
One might object that because hypnotic procedures generally 
involve deep relaxation and mental absorption (Rainville and 
Price, 2003). 
Multiple experiments have demonstrated that attention, 
expectation and hypnosis may influence information processing 
in the human brain (Kosslyn, Thompson, Costantini-Ferrando, 
Alpert, & Spiegel, 2000; Raz, 2004b; Raz & Buhle, 2006; Raz, 
Fan, & Posner, 2005; Raz et al., 2003b; Raz, Shapiro, Fan, & 
Posner, 2002; Wager et al., 2004). Both endogenous, top-down 
control, and exogenous, bottom-up capture of attention, enhance 
performance by affecting relative increases in neural activity in 
a given sensory system (Raz & Buhle, 2006). 
“Hypnosis typically involves an introduction to the procedure 
during which the subject is told that suggestions for imaginative 
experiences will be presented. The hypnotic induction is an 
extended initial suggestion for using one’s imagination, and may 
contain further elaborations of the introduction. A hypnotic 
procedure is used to encourage and evaluate responses to 
suggestions. When using hypnosis, one person (the subject) is 
guided by another (the hypnotist) to respond to suggestions for 
changes in subjective experience, alterations in perception, 
sensation, emotion, thought or behavior. Persons can also learn 
self-hypnosis, which is the act of administering hypnotic 
procedures on one’s own.” (APA Division 30: Green, J.P., 
Barabasz, A.F., Barrett, D., & Montgomery, G.H., 2005). 
Hypnotherapy is a form of psychotherapy used to create 
unconscious change in the patient in the form of new responses, 
thoughts, attitudes, behaviors or feelings. It is undertaken with a 
subject in hypnosis.  
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In the 1950s, the psychiatrist Milton H. Erickson developed a 
radically new approach to hypnotism, which has subsequently 
become known as "Ericksonian hypnotherapy". Erickson made 
use of an informal conversational approach with many clients 
and complex language patterns, and therapeutic strategies 
(Grinder J., Bandler R., 1976). 
In 1974, Theodore Barber and his colleagues published an 
influential review of the research which argued, following the 
earlier social psychology of Theodore R. Sarbin, that hypnotism 
was better understood not as a "special state" but as the result of 
normal psychological variables, such as active imagination, 
expectation, appropriate attitudes, and motivation (Barber, T. X., 
Spanos, N. P., Chaves, J. F., 1974).   
Barber introduced the term "cognitive-behavioral" to describe 
the nonstate theory of hypnotism, and discussed its application 
to behavior therapy. 
The Cognitive behavioural hypnotherapy (CBH) is an integrated 
psychological therapy employing clinical hypnosis and cognitive 
behavioural therapy (CBT) (Robertson D., 2012).  
The use of CBT in conjunction with hypnotherapy may result in 
greater treatment effectiveness. A meta-analysis of eight 
different researches revealed "a 70% greater improvement" for 
patients undergoing an integrated treatment to those using CBT 
only (Kirsch I., Montgomery G., Sapirstein G., 1995).  
In 1995, the US National Institutes of Health (NIH), established 
a Technology Assessment Conference that compiled an official 
statement entitled "Integration of Behavioral & Relaxation 
Approaches into the Treatment of Chronic Pain & Insomnia". 
This is an extensive report that includes a statement on the 
existing research in relation to hypnotherapy for chronic pain. It 
concludes that: ‘The evidence supporting the effectiveness of 
hypnosis in alleviating chronic pain associated with cancer 
seems strong. In addition, the panel was presented with other 
data suggesting the effectiveness of hypnosis in other chronic 
pain conditions, which include irritable bowel syndrome, oral 
mucositis (pain and swelling of the mucus membrane), 
temporomandibular disorders (jaw pain), and tension 
headaches.’ (NIH, 1995). 
In 2001, the Professional Affairs Board of the British 
Psychological Society (BPS) commissioned a working party of 
expert psychologists to publish a report entitled The Nature of 
Hypnosis (The British Psychological Society, 2001).  Its remit 
was 'to provide a considered statement about hypnosis and 
important issues concerning its application and practice in a 
range of contexts, notably for clinical purposes, forensic 
investigation, academic research, entertainment and training.' 
The report provides a concise (c. 20 pages) summary of the 
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current scientific research on hypnosis. It opens with the 
following introductory remark: 
- ‘Hypnosis is a valid subject for scientific study and research 
and a proven therapeutic medium.’ 
With regard to the therapeutic uses of hypnosis, the report said: 
- ‘Enough studies have now accumulated to suggest that the 
inclusion of hypnotic procedures may be beneficial in the 
management and treatment of a wide range of conditions and 
problems encountered in the practice of medicine, psychiatry 
and psychotherapy.’ 
In 2007, a meta-analysis of the efficacy of hypnotherapy was 
published by Flammer E. and Alladin A.: they discovered that 
Hypnotherapy is claimed to be effective in treatment of 
psychosomatic disorders. A meta-analysis was conducted with 
21 randomized, controlled clinical studies to evaluate efficacy of 
hypnosis in psychosomatic disorders. Studies compared patients 
exclusively treated with hypnotherapy to untreated controls. 
Studies providing adjunctive standard medical care in either 
treatment condition were also admitted. Hypnotherapy was 
categorized into classic (n = 9), mixed form (n = 5), and modern 
(n = 3). Results showed the weighted mean effect size for 21 
studies was d (+) = .61 (p = .0000). Regression of outcome on 
treatment dose failed to show a significant relationship. 
Numerical values for correlation between suggestibility and 
outcome were only reported in three studies (mean r = .31). The 
meta-analysis clearly indicates hypnotherapy is highly effective 
in treatment of psychosomatic disorders. 
Results of scientific studies demonstrate that hypnosis is an 
effective and efficient means of developing the resources of 
people suffering from serious illness (Handel DL., 2001, 2008, 
2010). After an average of few hypnotherapy sessions in 
Palliative Care, patients are able to locate previously 
unexploited resources within themselves and are able to become 
autonomous in the use of self-hypnosis. The major benefit 
reported concerned a reduction in anxiety (Teike Luethi F, 
Currat T, Spencer B, Jayet N, Cantin B., 2012; Brugnoli M.P., 
2014). 
Clinical hypnosis in  palliative care is indicated for patients with 
any serious illness and who have physical, psychological, social, 
or spiritual distress as a result of the treatment they are seeking 
or receiving (Brugnoli M.P., 2014; Handel DL., 2001).  
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Clinical Hypnosis in Palliative Care  
 
Palliative care is the specialized medical care for people with 
serious illnesses. It focuses on providing patients with relief 
from the symptoms, pain, and stress of a serious illness, 
whatever the diagnosis. 
Palliative medicine utilizes a multidisciplinary approach in 
patient care to relief pain and symptoms (American Academy of 
Hospice and Palliative Medicine, 2013; Delgado-Guay, M. O.; 
Parsons, H. A.; Li, Z.; Palmer, L. J.; Bruera, E., 2009). 
In the past decade, there has been a dramatic increase in the 
number and quality of research studies examining effects of 
clinical hypnosis on pain and anxiety. 
Specifically, clinicians treating patients with chronic pain in 
Palliative Care should:  
- include hypnotic suggestions that impact all of the 
neurophysiological processes that may underlie a patient’s pain;  
- include suggestions that impact other key quality of life 
domains (e.g., anxiety, sleep quality, relief from nausea in 
chemotherapy); 
- train patients in the use of self-hypnosis to achieve immediate 
pain relief;   
- provide audio recordings of treatment sessions to enhance 
treatment effects  
We perceive pain, anxiety and suffering as separate entities.  
The physical, anatomic, and neurochemical expression of pain is 
treated by physical therapy, medicines, nerve block, electric 
stimulators, and surgery.  
The suffering component involves the patient's  
(1) nonacceptance,  
(2) fear of the unknown and anxiety,  
(3) pessimistic evaluation of the meaning of pain and 
depression,  
(4) feeling of no time limit to suffering, and  
(5) often self-destructive feelings of guilt and resentment.  
These emotions and imaginings are quite amenable to good 
hypnotherapy. When suffering is removed, pain tends to become 
tolerable or may even disappear (Ewin DM., 1978, 1992, 2001). 
Clinical Hypnosis provides relief from pain, anxiety and other 
distressing symptoms. 
Several reviews and systematic research studies confirm that 
psychological interventions and clinical hypnosis are efficacious 
in the treatment of acute and chronic pain (Vannoni S., Brugnoli 
A., 1971; Brugnoli A. 1974a, 1974b; Ewin DM., 1978, 1992, 
2001), in disability and cancer-related pain (Spiegel and Bloom, 
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1983; Jensen, Hanley, Engel, Romano, Barber, Cardenas et al., 
2005). 
For both chronic and acute pain conditions:  
(1) hypnotic analgesia consistently results in greater decreases in 
a variety of pain outcomes compared to no treatment/standard 
care;  
(2) hypnosis frequently out-performs non-hypnotic interventions 
(e.g. education, supportive therapy) in terms of reductions in 
pain-related outcomes; and  
(3) hypnosis performs similarly to treatments that contain 
hypnotic elements (such as progressive muscle relaxation), but 
is not surpassed in efficacy by these alternative treatments 
(Stoelb BL, Molton IR, Jensen MP, Patterson DR., 2009; 
Patterson DR, Jensen MP, Wiechman SA, Sharar SR., 2010). 
The brain imaging studies are demonstrating the 
neurophysiological changes that can and do occur as a result of 
hypnotic analgesia treatment. Studies using fMRI and PET scan 
technology have revealed that a number of brain structures 
involved in the perception of pain (e.g. somatosensory cortex, 
anterior cingulate cortex, insula) are demonstrably affected 
through hypnotic suggestion (Rainville, Duncan, Price, Carrier, 
and Bushnell, 1997; Hofbauer, Rainville, Duncan and Bushnell, 
2001; Derbyshire, Whalley, Stenger and Oakley, 2004). 
Many common potential problems can arise in chronic illnesses 
and during the last days and hours of a patient's life (Strang P., 
Strang S., Hultborn R., Arnér S., 2004). 
Suffering from uncontrolled pain is a significant fear of those 
with chronic illnesses and at end of life (Agency for Healthcare 
Research and Quality, 2013). 
We can consider clinical hypnosis as an adjuvant for 
pharmachological therapies, in pain therapy (Brugnoli M.P., 
2014). 
Pain is a serious health care problem and there is increasing 
evidence to support the use of hypnosis for pain management. 
Clinical Hypnosis is efficacious for managing chronic pain and 
hypnosis interventions consistently produce significant 
decreases in pain associated with a variety of chronic-pain 
problems. Also, hypnosis is generally found to be more effective 
than nonhypnotic interventions such as attention, physical 
therapy, and education. Most of the hypnosis interventions for 
chronic pain include instructions in self-hypnosis (Brugnoli 
M.P., 2014; Adachi T, Fujino H, Nakae A, Mashimo T, Sasaki 
J., 2014; Elkins G, Jensen MP, Patterson DR., 2007; Elkins G, 
Johnson A, Fisher W., 2012). 
Anxiety is addressed as a special form of mind/body problem 
involving deep interaction between mental and physical distress 
in chronic illnesses. 
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The scientific researches suggest that for those who experience 
significantly impairing and/or distressing anxiety, it often goes 
undertreated (OttoMW, Smits JA, Reese HE., 2004). 
Hypnosis and self-hypnosis training represents a rapid, cost-
effective, and safe adjuvant or alternative to medication for the 
treatment of anxiety-related conditions (Hammond DC., 2010; 
Untas A, Chauveau P, Dupré-Goudable C, Kolko A, Lakdja F, 
Cazenave N., 2013). 
Cognitive hypnotherapy, is applied to the treatment of anxiety 
disorders (Golden WL.,2012). 
Rapid and sustained relief of severe anxiety is necessary to 
achieve comfort at the end of life: skilled additions of 
psychological therapies as clinical hypnosis with breathing 
exercises, and combined pharmacotherapy, led to control of 
anxiety (Udo I. Gash A., 2012). 
The dying process is characterized by feelings of sadness and 
fear. It is normal for patients at the end of life to worry and 
grieve the loss of their health. However, when these feelings 
become excessive and interfere with all aspects of the patient's 
life, they are abnormal responses to the stress of terminal illness.  
Depression in chronic illnesses and in Palliative Care, is a state 
of low mood and aversion to activity that can affect a person's 
thoughts, behavior, feelings and sense of well-being (Salmans, 
S.,1997).   
Depressed people feel sad, anxious, empty, hopeless, worried, 
helpless, worthless, guilty, irritable, hurt, or restless. They may 
lose interest in activities that once were pleasurable, experience 
loss of appetite or overeating, have problems concentrating, 
remembering details, or making decisions, and may 
contemplate, attempt, or commit suicide.  
Insomnia, excessive sleeping, fatigue, loss of energy, or aches, 
pains, or digestive problems that are resistant to treatment may 
also be present (NIMH, 2012). 
Screening for depression in terminally ill patients can optimize 
their physical comfort at the end of life and provide them the 
opportunity to confront and prepare for death (Braun UK, Kunik 
ME, Pham C., 2008). 
The core issue regarding antidepressants for many clinicians is 
whether they perform significantly better than placebos. 
However, The enhanced effects of psychotherapy utilizing 
hypnosis offer a means of avoiding most, if not all, of the 
problems associated with the use of antidepressants as a primary 
form of treatment (Yapko MD., 2013; Frischholz EJ., 2013; 
Lankton S.,2013).  
Alladin A, and Alibhai A., (2007), to investigate the 
effectiveness of cognitive hypnotherapy (CH), hypnosis 
combined with cognitive-behavioral therapy (CBT), on 
depression, studied 84 patients with depression: they were 
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randomly assigned to 16 weeks of treatment of either CH or 
CBT alone. At the end of treatment, patients from both groups 
significantly improved compared to baseline scores. However, 
the CH group produced significantly larger changes in Beck 
Depression Inventory, Beck Anxiety Inventory, and Beck 
Hopelessness Scale. The effect size was maintained at 6-month 
and 12-month follow-ups. This study represents the first 
controlled comparison of hypnotherapy with a well-established 
psychotherapy for depression, meeting the APA criteria for a 
"probably efficacious" treatment for depression (Alladin A., 
Alibhai A.,2007). 
Evidence-based strategies, including hypnosis, are studied  in 
the context of cognitive hypnotherapy for depression, to 
illustrate how expectancy effect can be maximized in 
psychotherapy and clinical hypnosis (Alladin A., 2013). 
During the final months of the life pain, anxiety, depression, 
fatigue, loss of appetite, dependency and feeling unwell are the 
most prevalent symptoms. Physical symptoms are more often 
treated than psychosocial symptoms. The number of medical 
disciplines involved in the patient's care decreased in the period 
before death, but the number of informal caregivers increased: 
many patients die peacefully (Georges JJ, Onwuteaka-Philipsen 
BD, van der Heide A, van der Wal G, van der Maas PJ., 2005).  
Relief of cancer-related symptoms is essential in the supportive 
and palliative care of cancer patients and in chronic illnesses. 
While apparently not painful for the patient, the association of 
the symptoms in severe chronic illnesses with impending death 
can create fear and uncertainty for those at the bedside.  
Nausea is a sensation of unease and discomfort in the upper 
stomach with an involuntary urge to vomit. It often, but not 
always, precedes vomiting. A person with chronic disease can 
suffer nausea and/or vomiting.  
Nausea is a non-specific symptom, which means that it has 
many possible causes. Some common causes of nausea are 
motion sickness, dizziness, headache, fainting, gastroenteritis 
(stomach infection), or the side effects of many medications 
including cancer chemotherapy. Nausea may also be caused by 
anxiety, and depression. Typically, it is  controlled using 
cyclizine; or other anti-emetics. In addition to nausea and 
vomiting following chemotherapy treatment, cancer patients can 
experience these side effects prior to a treatment session, the so-
called anticipatory nausea and vomiting. 
Richardson, Smith, McCall, Richardson, Pilkington, and Kirsch 
(2007) systematically reviewed the research evidence on the 
effectiveness of hypnosis for cancer chemotherapy-induced 
nausea and vomiting (CINV). A comprehensive search of major 
biomedical databases including MEDLINE, EMBASE, 
ClNAHL, PsycINFO and the Cochrane Library was conducted. 
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Specialist complementary and alternative medicine databases 
were searched and efforts were made to identify unpublished 
and ongoing research. Citations were included from the 
databases' inception to March 2005. Randomized controlled 
trials (RCTs) were appraised and meta-analysis undertaken. 
Clinical commentaries were obtained. Six RCTs evaluating the 
effectiveness of hypnosis in CINV were found. In five of these 
studies the participants were children. Studies report positive 
results including statistically significant reductions in 
anticipatory and CINV. Meta-analysis revealed a large effect 
size of hypnotic treatment when compared with treatment as 
usual, and the effect was at least as large as that of cognitive-
behavioural therapy. Meta-analysis has demonstrated that 
hypnosis could be a clinically valuable intervention for 
anticipatory and CINV in children with cancer. 
The scientific experience highlights the potential value of 
hypnosis in the management of anticipatory nausea and 
vomiting in chemotherapy; furthermore, the susceptibility to 
anticipatory nausea and vomiting is discussed under the 
psychoanalytic point of view (Marchioro G, Azzarello G, 
Viviani F, Barbato F, Pavanetto M, Rosetti F, Pappagallo GL, 
Vinante O., 2000). 
Adverse effects of chemotherapy can be severe and can have a 
significant impact on a person's quality of life.  
With chemotherapy treatment increasingly administered in the 
ambulatory setting, there is a need for patients to be informed 
about effective self-care strategies to manage treatment adverse 
effects. Relevant studies published in peer-reviewed journals 
between 1980 and August 2007 was conducted to identify self-
care strategies for reducing nausea/vomiting, constipation, 
diarrhea, fatigue, dyspnea. They recognized reasonable quality 
of nonpharmacologic strategies for managing common 
chemotherapy adverse effects, as cognitive distraction, exercise, 
hypnosis, relaxation, and systematic desensitization to reduce 
symptoms in cancer (Lotfi-Jam K, Carey M, Jefford M, 
Schofield P, Charleson C, Aranda S, 2008; Syrjala KL, 
Cummings C, Donaldson GW., 1992). 
Hypnotherapy in palliation, can be useful in the management of 
anxiety, discomfort, and psychosomatic symptoms, all of which 
may contribute to a complaint of dyspnea. 
The case illustrates the strength of hypnosis for accessing 
resources outside of conscious awareness and use of dissociative 
language to both support and alter the patient's defenses (Anbar 
RD, Linden JH., 2010). 
The focus of the hypnotherapy in Palliative Care, is to 
ameliorate the effects of pain and anxiety to restore a level of 
psychological and physical wellbeing(Marcus J, Elkins G, Mott 
F., 2003).  
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The Research aims 
 
Hypnosis offers the possibility to create a strong therapeutic 
alliance between the caregiver and the patient, an alliance 
characterized by motivation, trust, and collaboration. Motivation 
is based on the desire the patient has to feel better, to reach a 
comfort zone, to find his/her own resources to face death; trust is 
reached as soon as the patient experiences the benefits of 
hypnotic suggestions and self-hypnosis; the collaboration with 
the hypnotist is a natural answer of gratitude and recognition for 
the physical and psychological benefits.  
 
The specific aims of this study are: 
 
1. to measure of hypnosis's influence and efficacy, as an 
adjuvant therapy, on pain in severe chronic diseases and 
in Palliative Care 
2. to measure of hypnosis's influence and efficacy, as an 
adjuvant therapy, on anxiety symptoms in severe chronic 
diseases and in Palliative Care 
3. to measure of hypnosis's influence and efficacy, as an 
adjuvant therapy, on the use of opioids in severe chronic 
diseases and in Palliative Care 
4. to demonstrate reliability and validity of the 
effectiveness of the use of hypnosis, and self-hypnosis to 
relief pain and anxiety in severe chronic illnesses and in 
Palliative Care for a long term follow-up (1 year and 2 
years). 
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CHAPTER 2  
 
 
MATERIALS AND METHODS 
 
 
 
Description of Study Design: Nonrandomized Clinical Trial 
 
Type of study: Research on primary data with a long-term 
follow-up 
 
This is a long term follow-up of treatment in a prospective 
observational non-randomized controlled study. 
We have enrolled in our study the patients with these severe 
chronic diseases: 
 
1. Cancer 
2. Neurological severe chronic diseases 
3. Rheumatologic severe chronic diseases 
 
All the patients enrolled in our study were diagnosed by the 
colleagues’specialists for these particular diseases. 
The patients were enrolled in 2 groups: 
 
1. The group with the intervention of hypnosis and self-
hypnosis as adjuvant therapy, added to the 
pharmachological therapy 
2. The group with no hypnosis intervention had only the 
pharmachological therapy 
 
The patients of the 2 groups, were all cured with the 
pharmachological therapy, and the group hypnosis with clinical 
hypnosis as adjuvant therapy, added to the pharmachological 
therapy, from the same physicians and pain therapist Dr. Maria 
Paola Brugnoli, Specializations in Anesthesia and Critical Care, 
Pain Therapy and Palliative Care, Hypnotherapist, at the 
Department of Anesthesia, Intensive care and Pain Therapy, 
University of Verona, Italy. The group Hypnosis had 2 therapist 
for the hypnosis interventions: Dr. Brugnoli (the principal 
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investigator) and Dr. Emanuela Pasin, Psychologist, 
Psychotherapist and Hypnotherapist, to avoid bias about 
administration and procedures about hypnosis and follow-up. 
When we enrolled the patiens, we would have like to organize a 
randomized study, but it was impossible to organize, because 
some patients asked to add clinical hypnosis to their therapies, to 
have a better quality of life; other patients would not to use 
hypnosis because they have fear. This was a clinical research 
with very suffering people in palliative care, and not with 
volounteers, so we have decided that patients could choose the 
group. 
 
Study Population 
 
The setting were the patients were cured and studied was the 
Department of Anestesiology, Intensive Care and Pain Therapy, 
at the University of Verona, Verona, Italy, Director Professor 
Enrico Polati. 
We cured the outpatiens affering to the Pain Therapy 
Ambulatory. 
 
 
Eligibility Criteria For Participants 
  
Inclusion criteria  
 Gender: both female and male participants are being 
studied 
 Age Limits: Minimum Age 18; maximum age no limits  
 Severe chronic disease: For both the 2 groups the 
patients must have a severe chronic disease:  
1. Cancer  ( C) 
2. Chronic Neurological diseases  (ND) 
3. Chronic Rheumatological diseases  (CRD) 
 All the patients of the 2 groups, are cured as outpatient at 
the Department of Anesthesia, Intensive Care and Pain 
Therapy, for chronic pain, only with a pharmacological 
therapy by the same physician: dr. Maria Paola Brugnoli.  
 All the patients of the 2 groups are only partially 
responder to conventional pharmachological therapies, 
but they do not want to increase the use of medicines. 
They do not want use anxiolitics for different 
motivations (as to drive the car, or to be always perfectly 
aware). 
 Chronic pain: where they were affected with Chronic 
pain and intensity VAS (0-100) = > 40 
 Anxiety: where they were affected by anxiety evaluated 
by the Hamilton Anxiety Scale (0-30)  
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where they were affected with a score of 1-30,  indicates 
mild, severe or less anxiety. 
 Patients must not have diagnosed severe cognitive 
disorders  
 Patients must not have diagnosed major psychiatric 
disorders, as schizophrenia 
 Patients enrolled in the group of hypnosis have to attend 
at least the 50% of the meeting on hypnosis techniques 
(they had to sign their attendance) 
 Patients enrolled in the 2 groups have the same type of 
pain: muscular pain, visceral pain and osteoarthritis pain, 
but not neuropathic pain (see exclusion criteria). 
 
Exclusion criteria 
 Children: age< 18 years 
 Patients with cognitive disorders 
 Patients with major psychiatric disorders as 
schizophrenia 
 Patient can be enrolled in the two groups only if they use 
only a pharmacological therapy with Opioids, NSAIDS 
and/or Corticosteroids 
 Patients cannot be enrolled if they use Antidepressants, 
Anxiolytixs or Antiepileptis, because they could be bias 
for the study of anxiety. 
 Patients cannot be enrolled if they suffer for neuropathic 
pain, for the use of Antidepressants or Antiepileptis, 
because they could be bias for the study of anxiety. 
 Patient cannot be enrolled if they use other therapies than 
only medicines as: psychotherapy, anesthesiological 
blocks, acupuncture, mesotherapy (they could be bias to 
study pain and anxiety). 
 Patients with less than 1 year expectation of life (one of 
the aim of the study is a long-term follow-up)  
(however, even if some patients were not enrolled in the 
study, they could have attended the hypnosis’ sessions). 
 Inability to perform informed consent 
Justification for the exclusion of Minors:  Subjects under 18 
years of age are excluded because the adjustment processes of 
children and adolescents are demonstrably dissimilar from those 
of adults, and because of these marked differences in coping and 
resilience patterns, psychosocial research generally does not 
combine work on children and adults in the same study.   
 
The recruitment procedure  
We would have organize a randomized study, but some patients 
would have liked to learn hypnosis, and some other would not, 
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because they had fear of hypnosis. Some other patients could not 
attend the hypnotic sessions due to their work. 
We decided to organize a nonrandomized clinical trial. 
This is a clinical trial in which the participants are not assigned 
by chance to different treatment groups. Participants may choose 
which group they want to be in: this is an ethical choose of the 
authors, considering that all patients have severe chronic 
illnesses and some of them are at the end of life. Although 
randomization is preferable because it helps to control for 
factors other than the intervention that may be responsible for 
differences in outcomes, non-randomized assignment may be 
necessary when randomization is not feasible or ethical.  
The specific purpose of this sequential clinical trial is to 
continuously compare the two treatments (group with hypnosis 
as adjuvant therapy and group without hypnosis) as data 
becomes available after the follow-up (1 and 2 years). 
The effect of the intervention is evaluated by comparing the 
group of subjects receiving a standard pharmacological 
intervention (control group) to the group receiving hypnosis as 
adjuvant therapy added to the pharmacological intervention. 
This study started on January 2014.  
The first six months, we enrolled 76 patients with severe chronic 
illnesses and in Palliative Care.  
Only 56 entered in the inclusion criteria, and 6 declined to 
participate to the study. 
We have studied 50 patients, divided in 2 groups (hypnosis and 
non hypnosis- the control group) 
 
Table 1: The Recruitment Procedure 
 
The first 6 months:  
1. To decide the criteria for 
subjects’selection  
 
2. Use of the subject selection criteria to 
identify suitable candidates 
 
3. The doctor invites all the patients to 
read about the study, assures them 
their decision will not affect care, and 
offers the info packet (information 
pages, and the consent form) 
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During the Phase 1 of the research program and recruitment, 
potential subjects have been given a packet that contains: 
 Introduction (first page of packet) and information  
 Informed consent – on white paper 
 Subject contact sheet (for the subject’s contact information) – on white 
paper 
 Written interview questionnaires  (VAS and HAMA) 
 Information on how to complete the questionnaires by section 
 Where they can complete questionnaire and where to place completed 
packet 
 
Steps by subject – After informed consent, instructions to 
subjects for maintaining confidentiality are provided. 
Subject consideration, recruitment, screening, and full 
participation in this study are without preference for race, socio-
economic level, or gender.   
 
The Informed consent 
 
The Informed consent provides all the important information 
about the study, so that potential participants can decide whether 
to enroll (or, if enrolled, to continue participating). Ensures that 
potential participants understand there are no risks and potential 
benefits of participating in the study. Stress that enrolling in 
(and staying in) a clinical study is completely voluntary. 
Because giving consent to participate in research is not a 
contract, participants can leave a study at any time. The 
researcher and the potential participants had discussions that 
included answering the participant's questions about the 
research. Participants of the two groups (hypnosis and no 
hypnosis) must be aware that they are free to limit their 
participation in the research study, or withdraw their 
participation altogether at any time. If there is an item on a 
questionnaire that the participant does not want to answer 
because it makes them feel uncomfortable, they are free to skip 
it. If there is an aspect of the treatment that they do not feel 
comfortable with, they are free to sit out. Furthermore, if the 
research study is making them uncomfortable, they are free to 
quit the study. 
All the important information about the study have also be given 
to the potential participant in a written document that is clear 
and easy to understand. All the patients signed the informed 
consent document to be enrolled in the study. This research 
study does not provide pharmachological intervention, added to 
the medicines the patiens take at the time of their recruitment. 
Participants also had the fundamental right of privacy. 
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Confidentiality means that participants' responses was only be 
seen by researchers who are directly involved in the study. 
Data and safety of data will be monitored by the Principal 
Investigator PI  (Dr. Maria Paola Brugnoli). All surveys will be 
de-identified and assigned a unique ID number prior to being 
entered into the data base.  De-identified questionnaires will be 
retained in a locked file. A memorandum of understanding will 
be executed by the principal investigator. 
 
 
Table 2: the Conceptual model of the research program 
 
 
The Study Design 
 
We have organized 2 groups of 25 patients each, with severe 
chronic illnesses, evolving in pain, anxiety and anxiety-related 
symptoms. 
All the patients of the 2 groups, were cured as outpatiens 
affering to the Pain Therapy Ambulatory, with conventional 
pharmacological therapy (FANS and/or opioids) by dr. Maria 
Paola Brugnoli, Anesthesiologist, Pain therapist and 
hypnotherapist at University of Verona, Department of 
46 
 
Anesthesiology, Intensive Care, and Pain Therapy, Hospital GB. 
Rossi, Verona, Italy.  
The conventional pharmacological therapy of the group of 
hypnosis, was added with the hypnosis’ adjuvant therapy, 
utilizing the group therapy with direct and indirect clinical 
hypnosis and self-hypnosis, by metaphors and relaxing musical 
video. This methodology to teach hypnosis, is conducted by Dr. 
Maria Paola Brugnoli (PI), with the assistance of Dr. Emanuela 
Pasin, Psychologist, and Dr. Maria Francesca Basile, 
Psychologist, that assisted dr Brugnoli during the assessment of 
the surveys, the follow-up and to organize the meeting to teach 
hypnosis to the patients. 
The training for this protocol for the assistant researcher 
included: 
 General information about the purpose and the protocol of the study. 
This is important so the research assistants could appropriately handle 
any problems that might come up in the study.  
 The importance of following the directions exactly to avoid 
unnecessary error in the research study. 
 An overview of what the instruments are measuring. Like 
understanding the purpose of the study, understanding the purpose of 
the instrument helped the research assistants answer unexpected 
questions during the study. 
 A detailed review of the protocol. 
 A demonstration of how the research procedures should be carried out.  
 The research assistant had an opportunity to practice the procedures.  
 
At the beginning of the study, all the Participants in the 
treatment group attended a 2 hours workshop with the Principal 
investigator and the research assistants, which covered the 
explanations for the skills and effective instructional practices. 
During the workshops, the principal investigator and the 2 
researches, used discussion, lecture, video demonstrations, small 
group discussions, and practice teaching demonstrations to 
educate participants about clinical hypnosis.  
 
Cluster 
 
The statistical analyses used in most scientific studies, are based 
on the assumption that observed outcomes in different patients 
treated by the same physician or in the same center are 
independent. This assumption is realistic in most double-blind 
pharmacologic studies. However, the validity of this assumption 
could be doubtful in trials assessing nonpharmacologic 
treatments, as the success of the treatment could partly depend 
on health care providers’ skill or expertise. Consequently, in 
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these trials, observations of participants treated by the same 
health care provider, may be correlated or “clustered.”  
To avoid the cluster for the clinical hypnosis treatment in our 
research, the patients of hypnosis group, were treated 
alternatively by two expert hypnotherapists: the principal 
investigator, Dr. Maria Paola Brugnoli and the assistant 
researcher, Dr. Emanuela Pasin. 
The 2 groups (table 3) were very homogeneous at baseline for: 
sex, age, diseases, use of opioids, VAS score and Hamilton 
score. 
 
Table 3: Characteristics of the 2 groups of the patients at 
baseline (2014) the time of the recruitment. 
 
Data expressed in n (%) or mean ± SD 
Demographic data and characteristics of the patients and of 
the 2 groups  
 
Fifty subjects – 14 men and 36 women - participated to the 
study. The average age of the subjects was 64 years, ranging 
from a minimum of 33 to a maximum of 83 years.  The patients 
suffered from 3 main types of disease:  
1. Rheumatic severe chronic diseases (Rheumatoid Arthritis and 
Autoimmune Rheumatic Diseases) (n=21); 
2. Neurologic severe chronic diseases (Multiple sclerosis; Parkinson's 
disease;  Spinal cord injuryies - ASIA B is having some sensory function 
below the injury, but no motor function; ASIA C some motor function 
below level of injury, but half the muscles cannot move against gravity- 
American Spinal Injury Association classification) (n=16); 
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3. Oncologic (Breast cancer, Colon cancer, Leukemia and Lymphoma) 
(n=13).  
As we can see on table n. 3, (demographic data) the two groups 
of patients were homogeneous for the features: age, diseases, 
use of opioids, VAS score at baseline, Hamilton score at 
baseline. 
Sixteen of them (32%) were administered with opioids for pain 
control.  
Half of the patients (n=25) were assigned to the group 
administered with rhe hypnotic protocol (hypnosis group), while 
the remaining 25 followed the conventional pharmachological 
pain therapies (control group). The two groups were 
homogeneous in the distribution of sex, type and subtypes of 
diseases, and use of opioids at baseline (Table 3)  
 
Measuring instruments 
 
After the workshop introductions on the first day, the pre-tests 
VAS and HAMA, were explained and administered. Participants 
were instructed to complete the questionnaire based on their 
own understanding of pain and anxiety. They were given 30 
minutes to complete the pre-test. All participants finished within 
this time period. 
After the last educational session about hypnosis, on the final 
day (after 1 year and after 2 years), participants were asked to 
complete the first  (1 year) and the second (2 years) follow-up 
with the post-test questionnaires VAS and HAMA. Again, they 
were given 30 minutes to complete the questionnaire.  
Participants in the control group did not attended the workshops 
of hypnosis. 
The control group also completed the same pre- and post test 
(after 1 year and after 2 years), just as the treatment group. 
Participants are asked to complete 2 evaluations (VAS and 
HAMA) before the first lesson, and the 2 long-term follow-up 
were made for all the patients of the 2 groups,  after 1 year 
(2015) and 2 years (2016) to compare the results of the 2 groups 
(group hypnosis and the control grpup). 
The evaluations for pain and anxiety were performed with the 
test: 
1. VAS the visual analogical scale for the evaluation of the pain  
2. HAMA Hamilton anxiety scale for the evaluation of the 
anxiety 
We have compared, in the statistical analysis, the increase and 
decrease of the use of opioids in the 2 groups. 
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1.VAS the visual analog scale for the evaluation of the pain. 
  
The visual analog scale (VAS) is a 
validated, psychometric response scale which can be used 
in questionnaires. It is a measurement instrument for subjective 
characteristics or attitudes that cannot be directly measured. 
When responding to a VAS item, respondents specify their level 
of agreement to a statement by indicating a position along a 
continuous line between two end-points. 
The visual analog scale (VAS) is one of the most commonly 
used measures of pain intensity in pain research. For pain 
intensity, the scale is most commonly anchored by “no pain” 
(score of 0) and “pain as bad as it could be” or “worst 
imaginable pain” (score of 100 [100-mm scale]). 
Method of administration. The pain VAS is self-completed by 
the respondent. The respondent is asked to place a line 
perpendicular to the VAS line at the point that represents their 
pain intensity. Scoring. Using a ruler, the score is determined by 
measuring the distance (mm) on the 10-cm line between the “no 
pain” anchor and the patient’s mark, providing a range of scores 
from 0 –100.  
Score interpretation. A higher score indicates greater pain 
intensity. Based on the distribution of pain VAS scores in 
postsurgical patients (knee replacement, hysterectomy, or 
laparoscopic myomectomy) who described their postoperative 
pain intensity as none, mild, moderate, or severe, the following 
cut points on the pain VAS have been recommended: no pain (0 
– 4 mm), mild pain (5– 44 mm), moderate pain (45–74 mm), 
and severe pain (75– 100 mm). 
 (Jensen MP, Chen C, Brugger AM., 2003). 
 
2.HAMA Hamilton anxiety scale: The Hamilton Anxiety Rating 
Scale  
It is a validated, clinician-rated evaluation whose purpose is to 
analyze the severity of anxiety. The scale consists of 14 items 
designed to assess the severity of a patient’s anxiety. Each of the 
14 items contains a number of symptoms (anxiety related 
symptoms) and each group of symptoms is rated on a scale of 
zero to four, with four being the most severe.  
The Hamilton Anxiety Rating Scale is composed of fourteen 
items. On the scale, each item is presented in a specific format.  
The items, correspond to the psychosomatic disorders related to 
anxiety, that are generally existing in severe chronic illnesses. 
Following the item number, the item itself is listed along with a 
brief description of the criterion. This description is in the form 
of a short phrase that elaborates on the item and provides 
specificity to the clinician regarding the appropriate evaluation. 
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Adjacent to each item is a five-point scale, displaying the 
numerals 0 to 4 outlined by a square. To learn more about the 
specific scoring regarding the Hamilton Anxiety Rating Scale, 
please proceed to the Scoring section. Each criterion on the scale 
is an independent feeling that is related to anxiety. The 
collaboration of each of these independently rated criteria are 
meant to evaluate a patient's anxiety severity. Below are the 
verbatim criteria and their brief definitions (as described above) 
as presented in the Hamilton Anxiety Rating Scale. 
 
We have choosen the Hamilton anxiety scale, because it is 
strongly related with the psychosomatic suffering of the patients. 
The items are: 
1. Anxious mood: Worries, anticipation of the worst, fearful 
anticipation, irritability. 
2. Tension: Feelings of tension, fatigability, startle response, 
moved to tears easily, trembling, feelings of restlessness, 
inability to relax. 
3. Fears: Of dark, of strangers, of being left alone, of animals, of 
traffic, of crowds. 
4. Insomnia: Difficulty in falling asleep, broken sleep, 
unsatisfying sleep and fatigue on waking, dreams, nightmares, 
night terrors. 
5. Intellectual: Difficulty in concentration, poor memory. 
6. Depressed mood: Loss of interest, lack of pleasure in hobbies, 
depression, early waking, diurnal swing. 
7. Somatic (muscular): Pains and aches, twitching, stiffness, 
myoclonic jerks, grinding of teeth, unsteady voice, increased 
muscular tone. 
8. Somatic (sensory): Tinnitus, blurring of vision, hot and cold 
flushes, feelings of weakness, pricking sensation. 
9. Cardiovascular symptoms: Tachycardia, palpitations, pain in 
chest, throbbing of vessels, fainting feelings, missing beat. 
10. Respiratory symptoms: Pressure or constriction in chest, 
choking feelings, sighing, dyspnea. 
11. Gastrointestinal symptoms: Difficulty in swallowing, wind 
abdominal pain, burning sensations, abdominal fullness, nausea, 
vomiting, borborygmi, looseness of bowels, loss of weight, 
constipation. 
12. Genitourinary symptoms: Frequency of micturition, urgency 
of micturition, amenorrhea, menorrhagia, development of 
frigidity, premature ejaculation, loss of libido, impotence. 
13. Autonomic symptoms: Dry mouth, flushing, pallor, tendency 
to sweat, giddiness, tension headache, raising of hair. 
14. Behavior at interview: Fidgeting, restlessness or pacing, 
tremor of hands, furrowed brow, strained face, sighing or rapid 
respiration, facial pallor, swallowing, etc."  
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The Hamilton Anxiety Rating Scale is a validated, clinician-
rated scale that is intended to provide an analysis of the severity 
of anxiety in adults, adolescents, and children. It is scored based 
upon the composite rating of fourteen individually evaluated 
criteria.  
The evaluator is instructed to assess the extent to which the 
patient displays the given criterion. Each item is scored 
independently based on a five-point, ratio scale. A rating of 0 
indicates that the feeling is not present in the patient. A rating of 
1 indicates mild prevalence of the feeling in the patient. A rating 
of 2 indicates moderate prevalence of the feeling in the patient. 
A rating of 3 indicates severe prevalence of the feeling in the 
patient. A rating of 4 indicates a very severe prevalence of the 
feeling in the patient. To implement the Hamilton Anxiety 
Rating Scale, the acting clinician proceeds through the fourteen 
items, evaluating each criterion independently in form of the 
five-point scale described above. 
Upon the completion of the evaluation, the clinician compiles a 
total, composite score based upon the summation of each of the 
14 individually rated items. This calculation will yield a 
comprehensive score in the range of 0 to 56. It has been 
predetermined that the results of the evaluation can be 
interpreted as follows. A score of 17 or less indicates mild 
anxiety severity. A score from 18 to 24 indicates mild to 
moderate anxiety severity. Lastly, a score of 25 to 30 indicates a 
moderate to severe anxiety severity (McDowell, I., Newell, C., 
& McDowell, I., 2006; Maier W, Buller R, Philipp M, Heuser I., 
1998; Hamilton M., 1959). 
In this study, HAMA enlightens the anxiety, the pain –related 
symptoms and the psychosomatic symptoms related to anxiety. 
All of these scores are used to compute an overarching score 
that indicates a person’s anxiety severity.  
We have chosen the Hamilton Anxiety Scale, because the items 
are related to the psychosomatic simptoms in severe chronic 
diseases and in palliative care. 
 
Hypnotizability and hypnotic induction profile 
 
Hypnotizability, which is the capacity to experience a transition 
into a hypnotic state and to perform hypnotic tasks, has a wide 
range of degrees, from difficult being hypnotizable at all to 
being able to respond with intriguing and even surprising 
intensity to hypnotic instructions. 
The history of hypnosis has been strongly influenced by the 
observation of highly hypnotizable subjects and their unusual 
abilities, such as hypnotic analgesia. 
In past decades, much effort has been devoted to rating most 
subjective phenomena in psychology and psychiatry, such as 
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psychiatric symptoms and disorders, pain, general anesthesia, 
consciousness, and coma. A wealth of scales and tests have been 
published so far, with a threefold role: (a) quantifying the 
intensity and severity of symptoms and their changes following 
treatment; (b) providing information on prognosis; and (c) 
enabling comparison between treatments. 
As a result, the concept of depth of anesthesia has been elusive, 
and no gold standard has emerged so far, despite the vast 
number of published studies analyzing the effectiveness of both 
clinical and neurophysiological parameters. Likewise, the 
problem of vegetative and minimally responsive states has no 
solution yet: a substantial controversy about the terminology, 
diagnosis, prognosis, perception of pain, and conscious 
awareness persists in the literature, despite a wealth of studies 
published in the past 40 years (Celesia, 2013). As a result, a 
mistaken diagnosis is still present in up to 43% of cases 
(Celesia, 2013; Schnakers et al., 2009; Facco E, Testoni I, 
Ronconi, Casiglia E, Zanette G. & David Spiegel, 2017). 
Hypnosis can be considered at the same time a procedure and its 
product (Barnier & Nash, 2008). The contradictory issue of 
hypnosis as an ASC (altered state of consciousness) has been 
debated in the literature (Kirsch, 2011; Mazzoni, Venneri, 
McGeown, & Kirsch, 2013; Pekala et al., 2010a, 2010b). A 
recent definition from Division 30 of the American 
Psychological Association emphasizes that hypnosis does 
involve an altered state of consciousness including absorption, 
dissociation, and enhanced capacity for response to suggestions 
(Elkins, Barabasz, Council, & Spiegel, 2015). 
The psychological features of hypnotizability are still ill defined, 
despite the availability of a wealth of data on the relationship 
between hypnotizability and personality, including the 
assessment of hypnoticlike experiences, personality traits (e.g., 
Minnesota Multiphasic Personality Inventory [MMPI]), 
cognitive control, suggestibility, imaginative involvement, 
absorption, dissociation, ego receptivity, and insight (H. Spiegel 
& Spiegel, 2004, pp.137–149). Some relationships between 
hypnotizability and absorption, dissociative experiences, 
proneness to fantasy, reaction time in a Go/No-Go Task, 
proneness to trust, and empathy have been established 
(Balthazard & Woody, 1992; Council & Green, 2004; Dienes et 
al., 2009; Frankel, 1990; Green, 1997; Green & Council, 2004; 
Green & Green, 2010; Wickramasekera & Szlyk, 2010; 
Zachariae, Jorgensen, & Christensen, 2000; Facco E, Testoni I, 
Ronconi, Casiglia E, Zanette G. & David Spiegel, 2017).  
Ian E. Wickramasekera and Janet P. Szlyk (2010) examined 
whether trait empathy is related to hypnotic ability and 
absorption. Sixty-four graduate students and mental health 
professionals completed the Harvard Group Scale of Hypnotic 
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Susceptibility, Form A; the Davis Interpersonal Reactivity 
Index; and the Tellegen Absorption Scale as measures of 
hypnotic ability, empathy, and absorption. Correlation analysis 
determined that statistically significant relationships exist 
between empathy and hypnotic ability (r = .41); empathy and 
absorption (r = .43); and absorption and hypnotic ability (r = 
.31). The results also indicate that empathy and absorption are 
both predictors of hypnotic ability, although absorption does not 
appear to contribute a statistically significant amount of the 
explained variance in hypnotizability that is independent of 
empathy. Itmaybe that the conceptual ground shared by both 
empathy and absorption is what predicts hypnotic ability 
(Wickramasekera, I. E., & Szlyk, J. P., 2010). 
Previous studies using the Minnesota Multiphasic Personality 
Inventory and other similar personality tests have failed to show 
any correlation with the available scales of hypnotizability 
(Laurence, Beaulieu-Prévost, & du Chéné, 2008). Focused 
attention and absorption are essential features of hypnosis, 
allowing the subject to dissociate from competing stimuli and 
thoughts (Spiegel H., 1977; D. Spiegel, 2013; H. Spiegel & 
Spiegel, 2004). Absorption is defined as total attention that fully 
engages one’s representational resources, leading to 
imperviousness to distracting events; it also involves an 
openness to absorbing and self-altering experiences (Tellegen & 
Atkinson, 1974). 
However, absorption might be more strongly related to difficult 
hypnotic performances than to easy ones (Balthazard & Woody, 
1992), while the correlation may also be influenced by 
contextual factors such as acquiescence (or “yeasaying”) and 
motivation consistency (Council & Green, 2004). Furthermore, 
some authors (Laurence et al., 2008) consider absorption more a 
cognitive pattern of response than a steady personality trait, 
related to motivation, attention, and capability of processing its 
objects. 
Dissociation, which is considered a relevant component of 
hypnosis, is a term with a wide range of psychological and 
psychiatric meanings (Brown, 2006; Frankel, 1990), ranging 
from psychological detachment (essential for fairness, serenity, 
wisdom, and judgment) to Bleuler’s psychiatric concept of 
spaltung (division, split) to a failure of normal integration of 
identity, memory, consciousness, and perception (American 
Psychiatric Association, 2013; D. Spiegel et al., 2013).  
This calls for a better definition of what is meant by dissociation 
in the context of hypnosis in order to avoid harmful 
misinterpretations. In short, hypnotizability is a complex 
phenomenon, which cannot be ascribed to a single personality 
trait or psychological attitude. Absorption and dissociation play 
a relevant but, perhaps, context sensitive role; also, other 
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features, like expectation, imagery, empathy, trust, capability to 
automatize, and ability to manage attentional resources may be 
involved as well and are worthy of further study (Kirenskaya, 
Novototsky-Vlasov, Chistyakov, & Zvonikov, 2011; Laurence 
et al., 2008; Muller, Bacht, Prochnow, Schramm, & Seitz, 2012; 
Rossi & Rossi, 2006). 
The scientific data imply some criticism of the available scales, 
which were introduced some 50 years ago and were constructed 
upon a definition of hypnosis mainly based on suggestibility. 
Furthermore, if hypnotizability is a stable capability, it should be 
theoretically possible to test it even outside of hypnotic 
induction (Hilgard, 1991). There is recent evidence of functional 
resting state brain subregion connectivity differences between 
high and low hypnotizable subjects undergoing functional 
magnetic resonance imaging (fMRI) scanning while not 
hypnotized (Hoeft et al., 2012). This difference involves greater 
functional connectivity between the left dorsolateral prefrontal 
cortex and the dorsal anterior cingulate gyrus among high 
compared to low hypnotizable individuals as measured using the 
Hypnotic Induction Profile. However, in a practical sense, 
hypnotizability can be assessed only with a formal induction of 
hypnosis including standardized tasks, which allow for scoring 
different hypnotic abilities. 
Clinical hypnosis is likely to function as a relaxation technique, 
decreasing sympathetic tone or increasing parasympathetic tone, 
or both, and, therefore, modulating anxiety and stress reactions. 
This also confirms the psychosomatic implications of hypnosis, 
allowing a subject to enhance control even over hemodynamic 
reactions to strongly stressful events, like surgery and chronic 
pain in severe chronic diseases (Facco, Pasquali, Zanette, & 
Casiglia, 2013; Lang et al., 2000; Facco E, Testoni I, Ronconi, 
Casiglia E, Zanette G. & David Spiegel, 2017) Thus making 
hypnosis a powerful tool for patient’s empowerment in facing 
both stressful physical and psychological events. 
Despite the continuous evolution of psychology and 
neuropsychology and the availability of a large number of 
studies, the process of developing a definition of hypnosis and 
hypnotizability is not yet concluded. Suggestibility, which 
played a central role in the past, is still uncertain and still 
defined and does not appear to be specific to hypnosis (Tasso & 
Perez, 2008). Furthermore, it is not clear whether hypnotic 
capacity is related to suggestibility or, rather, to the subject’s 
trust, motivation, and cognitive flexibility, since they may lead 
one to effectively follow the same hypnotic instructions for very 
different reasons (Lifshitz, M., Howells, C., & Raz, A., 2012). 
To summarize, there is a need to reappraise the concepts of 
hypnosis, hypnotizability, and its scales after some half century 
since their introduction. This might lead to a better definition of 
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hypnosis, more congruent with a neurophysiological perspective 
(Facco E, Testoni I, Ronconi, Casiglia E, Zanette G. & David 
Spiegel, 2017). 
Today, hypnotizability and the hypnotic induction profile are 
used in experimental neurophysiological studies with volunteers.  
Not always, they are used in clinical studies with patients. 
Indeed, to study the hypnotic induction profile, we must induce 
in hypnosis the patients, and sometimes they avoid the 
experiment, because they have fear of hypnosis. 
Medical studies must consider, individual ethics (protection of 
the individual), the respect of the patient and collective ethics 
(benefit for society) (Palmer CR., 1993). 
In our study, we could have not to organize and to study the 
hypnotic induction profile, because 11/25 patients of the control 
group (no-hypnosis), avoided the test (every hypnotical test is 
made under hypnosis) because they had fear of hypnosis.  
We have decided, as other authors have done in clinical studies 
of hypnosis, for respecting the patients, not use any hypnotic 
induction profile.  
 
Treatment procedures 
 
 The overall goal of the treatment was to teach clinical hypnosis and self-
hypnosis to the patients, as added therapy to the pharmacological therapy, 
to relief pain and anxiety 
 The treatment lasted two years. 
 The  participants at the hypnosis group met for the treatment: two hours 
once per week, every week for two years 
 They had to attend the 50% of the lessons in one year 
 Each treatment meeting lasted: two hours. 
 The treatment meetings held at the Department of Anesthesia, Intensive 
Care and Pain Therapy, at the University of Verona, Italy, in the meeting 
room: the participants could have been induced in hypnosis, while sitting 
in their chairs. 
 The typical format of each meeting was a workshop teorical-practical: the 
first hour the explanation of the techniques and the feedback for the 
previous techniques explained (if they had difficulties to do by themselves 
at home); the second hour to try with the first or the second investigator a 
practical tecniques all together in group. 
 A series of workshops of 2 hours, every week, for 2 years, are conducted 
on chronic pain assessment and management of anxiety and related 
symptoms, teaching directly to the patients of the hypnosis group, how to 
use the hypnosis and the self-hypnotic techniques.  
 The lessons are theoretical and practical. 
 The deteiled descriptions of the techniques of clinical hypnosis used in this 
research, are in the chapter N.5 
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The hypnotherapy group is a group therapy, where the people 
context and group process is explicitly utilized with clinical 
hypnosis as a mechanism of change by developing the 
manifestations of conscious energy, exploring and examining 
interpersonal relationships within the group, to discover the 
benefits of pain and anxiety relief in chronic illnesses and 
cancer. 
At the same time, all the patients of the two groups were cured 
with a pharmachological therapy for pain therapy, by the 
principal investigator, Dr. Maria Paola Brugnoli. 
The control group (no hypnosis) was cured only with the 
conventional pharmacological therapy. 
Clinical hypnosis can be considered in this research, a 
nonpharmacological intervention as “adjuvant” in pain therapy. 
Nonpharmacologic approaches and hypnosis, are intended to 
supplement, not substitute for, the pharmacologic or invasive 
techniques described.  
Nonpharmacologic interventions as clinical hypnosis, are 
appropriate in chronic diseases, in cancer patients and in 
Palliative Care, for the patient who:  
1) finds such interventions appealing;  
2) expresses anxiety or fear, as long as the anxiety is not 
incapacitating or due to a medical or psychiatric condition that 
has a –non specific treatment;  
3) may benefit from avoiding or reducing drug therapy (e.g., 
history of adverse reactions, fear of or physiological reason to 
avoid oversedation);  
4) is likely to experience and need to cope with a prolonged 
interval of postoperative pain, particularly if punctuated by 
recurrent episodes of intense treatment, or procedure–related 
pain;   
5) has incomplete pain relief following appropriate 
pharmacologic interventions. Cognitive–behavioral approaches 
include preparatory information, simple relaxation, imagery and 
hypnosis. Physical therapeutic agents and modalities include 
application of superficial heat or cold, massage, exercise, 
immobility, and electroanalgesia such as TENS therapy or 
electroacupuncture; 
6) for physical and psychological suffering relief, and in 
Palliative Care at the end of life. 
The cognitive–behavioral strategies, require greater professional 
involvement; these include complex imagery, hypnosis, 
biofeedback, mindfulness and combined therapies. Such 
strategies can be commonly applied when patients have acute or 
chronic pain. 
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The techniques of clinical hypnosis for pain and anxiety 
relief in severe chronic illnesses and in palliative care 
 
Following are described the details of the thechniques of clinical 
hypnosis used in this research in 2 years of hypnotic training for 
the hypnosis’ group. 
In the two years of hypnotical training with the patients, I have 
explained them several different tecniques, because using 
hypnosis and self-hypnosis in severe chronic illnesses and in 
palliative care, the patients must be choose from different 
techniques, which are the best practice for themself. 
Self- hypnosis is the way to use hypnosis alone, without the 
therapist. 
Self-hypnosis is a naturally occurring state of mind which can be 
defined as a heightened state of focused concentration. With it, 
you can change your thinking, kick bad habits, and take control 
of the person you are, along with relaxation and destressing 
from everyday life. It's similar to meditation and results in a 
better you. 
Self-hypnosis is used extensively in modern hypnotherapy. It 
can take the form of hypnosis carried out by means of a learned 
routine. Hypnosis may help pain 
management, anxiety, depression, sleep disorders, asthma, and 
skin conditions. When this practice is mastered, it can improve 
concentration, recall, enhance problem solving, alleviate 
headaches and even improve one's control of emotions. 
Steps commonly used for self-hypnosis:  
 
Self-Hypnosis requires four distinct steps. 
Step 1: Motivation. Without proper motivation, an individual 
can find very difficult to practice self-hypnosis 
Step 2: Relaxation of the body and mind: The individual must be 
thoroughly relaxed and must set aside time to perform this act. 
Additionally, distractions should be eliminated as full attention 
is needed. 
Step 3: Concentration: the individual needs to concentrate 
completely as energy is generated each time the mind focuses on 
a single image. 
Step 4: Directing: This is an option used only when the 
individual wants to work on a specific goal. The individual must 
direct their concentration on visualizing the desired result (Adi 
Da Samraj, 2005; Austin, J. H.,1999). 
We have added other important steps: 
Step 5: Resilience: Resilience is that ineffable quality that 
allows some people to be knocked down by life and come back 
stronger than ever. Rather than letting failure overcome them 
and drain their resolve, they find a way to rise from the 
suffering. 
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Step 6: Self-Communication: Mastering communication with 
ourselves determines our quality of life as it determines our 
ability to experience life as we would like. 
Step 7: Empathy: Empathy is the capacity to understand or feel 
what another person is experiencing from within the other 
person's frame of reference, i.e., the capacity to place oneself in 
another's position. There are many definitions for empathy that 
encompass a broad range of emotional states. Types of empathy 
include cognitive empathy, emotional empathy, 
and somatic empathy. Self – hypnosis can help the patients to 
improve these skills. 
Step 8: Compassion: Compassion and self-compassion 
motivates people to go out of their way to help the physical, 
spiritual, or emotional hurts and pains of another. 
 
The Technique of the different interpretation of the symptoms  
 
When a state of a lighter or deeper relaxation is achieved 
through different techniques,  the patient is trained as to how to 
interpret the feeling of chronic pain coming from a specific 
place in the body and to transform it slowly from a feeling of 
pain to a feeling of different nature, for example, light or 
medium tension, moderate pressure, beneficial warmth or  cold 
sensation of anesthetizing nature. 
 
Example of anesthesia to one hand 
“… While in a state of relaxation, you can imagine immersing  
your hand in a container of melting ice cubes and from the wrist 
up to the tip of your fingers the ice acts on your hand like a very 
powerful anesthesia … making it feel more and more 
insensitive. You will feel your hand becoming increasingly  
insensitive … and the anesthesia will increase. You will also 
know that the anesthesia will last until you repeat  to yourself for 
three times “ Everything is normal ”. 
 
Exercise “warm hands” 
Duration: 5 or also only 3 minutes. 
During this exercise you will repeat to yourselves: 
“ MY HANDS ARE WARM” 
During the period of “deep relaxation “ you will imagine to keep 
your hand in front of the flames of an open oven, or under a 
solar lamp (UVB lamp), or immersed in hot water or any other 
thought of this kind that might come easy to you. 
We can help the patient teaching him to visualize himself in a 
beautiful place that help him with tese new sensations instead of 
the pain. 
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The Technique of the transferred symptoms 
After achieving relatively strong analgesia in a certain part of 
the body with the techniques described above, you aim to 
mentally transfer the analgesia to another part of the body (for 
instance, instance from the hands to the abdomen or to the back) 
obtaining this way a gradual and progressive reduction of the 
global suffering. ….in a state of well-being… 
 
The Technique of the transport of the symptom 
When the patient has achieved a medium or better a deeper state 
of relaxation, you do an intense analgesia on one hand, 
preferably the one that is most used. 
You then proceed by moving the analogized hand on to the 
painful side of the body, or wherever you want to direct the 
analgesia. 
In this way with repeated procedures, you can obtain a good 
decrease of the suffering part of the body, especially if this pain 
has not been there for a very long time. ….in a state of well-
being… 
 
The Technique of the positive visualizations  
(for pain or anxiety relief) 
When the patient is always in a state of relaxation or in medium 
hypnosis status, you introduce particular visualizations that will 
cause after a certain time, major feeling visualization, which is 
capable of modify the painful information in the central nervous 
system, and therefore, reduce the pain to the patient. 
Let’s have an example of a complete hyposis induction: 
 
The technique for the desensitization of the pain 
During the deep hypnotic status, the patient does not seem to 
react to the surrounding environment and usually seems to have 
a reduced sensitivity to painful stimulation, this happens even if 
you can have some or all the reflexive or vegetative signs of the 
painful stimulation. 
The best use, therefore, for this technique is to induce deep 
relaxation up until the unconscious can register and activate 
through hypnotic suggestion a minor sensitivity to pain for a 
longer time even in a state of normal awakening, 
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The use of this technique is to diminish the anxiety connected 
with pain, in the case of headaches where besides the body pain, 
a great emotional dysfunction arises, also in the case of the 
phantom arm or leg after the amputation of an arm or leg or in 
the chronic pain of cancer patients. 
The methods most used during the state of deep relaxation or 
hypnosis are: 
 Direct instructions for the reduction of pain. 
 The use of metaphors. 
 The transportation of the painful symptom. 
 The  detachment  of pain through imagination. 
The Technique of the partial or total hypnotic amnesia  
 
(for pain or anxiety relief) 
 
Furthermore, for this technique, you need the patient to be in a 
medium or deep hypnotic state. It ‘s possible to achieve a better 
result by following this procedure: 
Taking the patient back to the well-being and healthy status 
before the illness started through specific questions. 
In this way, the patient will eventually forget the memories of 
the bad experiences, which are related to his pain and in some 
cases also forget the memories of the anxiety, which is related to 
the pain in chronic diseases. 
 
The Technique of the activation of a type of conditioned reflex 
This technique called the “non painful  pain” uses the same 
methods that Pavlov applied to dogs.  He created a typical 
conditioned reflex on dogs by showing them the food together 
with or soon after a painful stimulation. After a certain number 
of tests depending also from the breed and the sex of the dog the 
painful stimulation was not felt thanks to the gratification of the 
food. 
Almost the same happens with the human beings' thanks to a 
mechanism of emotional restructuring   in the perception of the 
painful stimulation at the level of the brain areas. 
During a deep status of relaxation, it is possible to activate a 
conditioned reflex through images and music preferred by the 
patient so that the pain is reduced: 
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The Technique of the switching of attention  
(for pain or anxiety relief) 
This method used by Kroger can be very useful for chronic pain, 
by training the patient to move his attention to those parts of the 
body, which are not affected by pain. 
Using gratifying visualization you train the patient to move his 
attention to another pleasant sensation of his body, which are 
past or present. This method is also useful in chronic pain when 
it is not too strong, but it is understood that the patient must 
participate actively to the visualization.  
Sometimes this is also easier than the previous systems,  
especially by suggesting  gratifying visualization. 
If the patient cannot do the self training you can use the 
following method: 
 
Method of the CD 
This consists of simply record the desired suggestion on a CD, 
and then listen to it  when you are relaxing. This will be very 
effective for people that have difficulty in visualizing. 
 
Hypnosis technique of the self-training of Shultz 
(for pain or anxiety relief) 
Autogenic training is a desensitation-relaxation 
technique developed by the German psychiatrist Johannes 
Heinrich Schultz and first published in 1932. The technique 
involves the daily practice of sessions that last around 15 
minutes. During each session, the practitioner repeats a set of 
visualisations that induce a state of relaxation. Each session can 
be practiced in a position chosen amongst a set of recommended 
postures (for example, lying down, sitting meditation, sitting 
like a rag doll). The technique can be used to alleviate 
many stress-induced psychosomatic disorders (Luthe, W. & 
Schultz, JH., 2001) 
 
We can use these exercises as techniques for self-hypnosis. 
When the patient has been well trained to practice the basic 
easier exercises of the self-training of Shultz, we can use these 
exercises during the hypnotic state, to obtain a good relief of 
pain. The simple exercises of the self-training of Shultz are: 
 Exercise of feeling heavy (for pain relief) 
 Exercise of the heat (for pain relief) 
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 Exercise of the heart (for anxiety relief) 
 Exercise of the breath (for anxiety relief) 
 Exercise of the abdomen (for pain relief) 
 Exercise of the cool forehead (for pain relief) 
All of the above exercises are suitable to the pain therapy, but 
we will consider here only a few examples 
 
Exercise of the cool forehead   
“My forehead is pleasantly cool”  
This can be another exercise  also used  for the pain-relief  
therapy  depending on  the patient’s personality and character.  
This is also a very important exercise used to control the chronic 
headache and as well used for different types of cancer. 
This is how to carry out the technique of the cool forehead: 
 
Concentrating on your forehead please repeat….. 
My head  is light ……… all the muscles of my face are rested 
…. 
I am calm…. Calm…. Perfectly calm.. in a state of great 
wellbeing…….. 
My forehead is cool… pleasantly cool….. Even more pleasantly 
cool……… 
The coolness is all around me and gives me wellbeing …… 
Wellbeing of the body and wellbeing of the mind…….. 
 
Repeat this formula between 5 and 10 times. 
 
Technique of the self- hypnosis for pain relief 
This is one of the most efficient techniques and is carried out in 
three phases: 
1. You are living a pleasant feeling in deep relaxation. 
2. You connect this feeling mentally to your symptoms. 
3. You are using it mentally to cancel your symptoms. 
The most efficient way to achieve this feeling is to repeat  this 
technique until you achieve your goal and sometimes this will 
take quite a while. 
Let’s imagine that we are going to use this technique of post-
hypnotic state, to achieve the following goal: “I can hear a very 
soft music that helps my pain." 
Phase 1 – You are living this moment in a status of relaxation.  
You relax for five minutes and concentrate on remembering the 
last time you could hear a soft music. 
You can hear the harmony of this music, and of all the other 
times that you heard soft music in your past. 
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You imagine hearing  this music in the ears of your mind;  
after you  have recaptured that moment, you go to phase 2. 
 
Phase 2 – you make the connection with the hypnosis.  
Yet again in a state of relaxation, you can see yourself in the 
different circumstances use the key words: 
“ Let me hear the soft sound of the music” and at that point, you 
will be hear. 
 
Phase 3 – you use this system to eliminate the pain: 
Try to examine the result of your experiment and if necessary 
repeat the whole procedure again. 
 
The body relaxation with hypnosis for the treatment of the 
acute pain in severe chronic illnesses 
 
With this exercise, you will be under hypnosis for different 
lengths of time, measured in minutes or seconds (acute pain in 
emergency and in critical care). 
 
ALWAYS THINK BEFORE YOU COUNT DOWN FROM 20 
TO 1:  
“Now I will sleep for X minutes meanwhile my pain will 
decrease."   
THEN begin to count down from 20, to 1. 
While you are practicing this experiment, you must use the 
following suggestion:  
 
EVERY TIME FASTER AND DEEPER… 
This  means of course that every time you will go to sleep with 
your eyes will close faster, and you will sleep more deeply. 
Try this exercise for different length of time. 
Try to do self-inductions that last  10, 15,  20 seconds. 
 
This technique can be used in the acute pain relief. 
 
The thechniques for deep states of hypnosis used for pain and 
suffering relief in palliative care 
Deepening hypnosis Suggestions: 
The deepening suggestions that are easiest to use in this situation 
are suggestions that relate to breathing, escalators, elevators and 
counting. Here are some examples. 
 
 - Breathing 
"And every single deep and natural breath you take allows you 
to deepen your relaxation." 
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- Counting 
"In a moment, I'm going to count from 10 down to 1… 
And in allowing each number to help your body grow more 
relaxed…  
your mind go more relaxed…  
so that certain thoughts just fade away…  
like sand slipping through your fingers… 
You can find that easy relaxation of mind and body… 
because of these words… just happens now… 
………………………… 
10 ……..easily relaxing all over again….. 
9 ……then… 
8 deeper still…. 
…. feeling great  
7…. 6….. 5…….  
mind and body relaxed…. 
4... relaxing more… 
… 3 then ……2… 
your deepening grew at …. 
1…. derful deep levels 
going deeper … 
………..That's right… 
 
- Elevators & Escalators 
In a moment, I'm going to ask you to imagine yourself at the top 
of an escalator. I'm going to count down from 10 to 1, as I say 
the number 10 in your imagination, step onto the escalator. 
………..Allow yourself to go deeper into relaxation with each 
number I say.  
…………When I reach the number 1, step off the escalator into 
a state of relaxation deeper than you've ever felt before. 
10 ………steps on the escalator and go much deeper… 
9…….. relaxing more and more with each number… 
8 ……….allowing yourself to go deeper and deeper with each 
number… 
7 ………….each number and each easy, natural breath you take 
helps you relax more fully… 
6…   
5…  doing deeper into relaxation… 
4… feeling relaxation flow and every area of your body… 
3…   
2…  allowing your body to feel a wonderful… at the 
relaxation… 
1…  now more deeply relaxed than ever before… 
 
After the hypnosis induction slowly…we return to being 
awake… 
now let’s take a deep breath…  
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and slowly…return to being awake… 
I regain my normal waking state.  
I can start my first movements of my feet and hands, 
calm....without rushing...slowly… 
I can start to slowly open my eyes........slowly......... 
and regain............always slowly...........my normal waking state,  
moving my arms and my legs..................... 
I move again.........good.  I am awake. 
 
 
Statistical analyses 
 
Data were summarized with means ± standard deviation (SD) or 
number (percentage), as appropiate. Comparisons of variables 
between groups were performed using the Person’s chi-squared, 
the Student’s T, or the Wilcoxon’s rank-sum tests, accordingly 
to the nature and the distribution of each variable.  
The associations of each variable with 1 year variations in VAS 
score, Hamilton’s score, and in pharmacological therapy were 
evaluated by linear, quantile, and binomial regression models, 
respectively. Multivariate models were performed using a 
stepwise backward approach, with a significance level for 
removal from the model of 0.20. 
Longitudinal scores of VAS and Hamilton were analysed using 
repeated measures ANOVA, in order to test the effectiveness of 
the hypnotic treatment and its potential interaction with the type 
of chronic disease.  
A significance level of 0.05 was adopted for the statistical tests.  
The analyses were all performed using STATA 14.1. 
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CHAPTER   3 
 
 
RESULTS 
 
 
The Figure 1 shows The Flow diagram of the progress through 
the phases of the parallel non-randomized trial of the two groups 
(that is enrolment, intervention, follow-up at 1 year and 2 years). 
We assessed all patients who were studied (intention-to-treat 
principle). The first 6 months of the study, we enrolled 76 
patients with severe chronic diseases, but only 55 were elegibily 
for the inclusion criteria. 5 patients declined to participate to the 
research. We enrolled 50 patients divided in 2 groups of 25 each 
for a non randomized controlled trial. At the first long term 
follow-up at 1 year we do not had drop-out. At the second long 
term follow-up at 2 years we had 7 drop-out in the hypnosis 
group and 6 drop-out in non-hypnosis group. 
 
Figure 1: The Flow diagram of the progress through the phases of the 
parallel trial of the two groups 
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Characteristics of the subjects and of the groups: 
Fifty subjects – 14 men and 36 women - participated to the 
study. The average age of the subjects was 64 years, ranging 
from a minimum of 33 to a  maximum of  83 years.  The patients 
suffered from 3 main types of disease: rheumatic (n=21), 
neurologic (n=16), or oncologic (n=13). Sixteen of them (32%) 
were administered with opioids for pain control.  
Half of the patients (n=25) were assigned to the group 
administered with rhe auto-hypnotic protocol (hypnosis groupb), 
while the remaining 25 followed the conventional pain therapies 
(control group). The two groups were homogeneous in the 
distribution of sex, type of disease, and use of opioids at 
baseline. 
Subjects administered with the hypnosis therapy had a greater 
reduction in pain and in anxiety. The VAS score at baseline was 
similar between the hypnosis and the control group (mean ± 
standard deviation, sd: 78 ± 16 and 77 ± 14, respectively); after 
1 year and 2 years, the score decreased in both groups compared 
to baseline score, and it was lower in the hypnosis compared to 
the control group (62 ± 15 and 46 ± 14, respectively).  
The Hamilton score in multivariate analysis, the treatment with 
hypnosis was associated with a greater decrease of 7 points 
compared to the control group, independently from the score at 
baseline. The decrease in VAS and Hamilton score were studied 
in the two therapy groups according to the type of disease 
suffered by the patients: rheumatic disease, neurologic disease, 
or cancer. For all the 3 types of disease, the reduction in both 
VAS and Hamilton scores was significantly greater in the 
subjects who were included in the hypnosis group, after 1 and 2 
years follow-up. Subjects in the hypnosis group were at lower 
risk of increasing the pharmacological treatment for pain 
control.  Only 16% of the subjects included in the hypnosis 
group had to increase the pharmacological treatment for pain 
control after 1 year, compared to 52% of the subjects in the 
control group (p-value for difference = 0.007). On the other 
hand, 56% of the subjects who were administered with opioids 
at baseline had to increase the pharmacological therapy, 
compared to 24% of the subjects who were not administered 
with opioids.(p-value = 0.023). 
The statistical analisis of the patients of the group 1 (hypnosis) 
after a long term follow-up 1 and 2 years of treatment with 
hypnosis as an adjuvant therapy for pain and anxiety, shows a 
significant statistical decrease of pain and anxiety compared 
with the control group, and have a less risk to have to increase 
the pharmacological treatment with opioids for pain relief. 
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The specific aims of this study were: 
 
1. to measure of hypnosis's influence and efficacy, as an 
adjuvant therapy, on pain in severe chronic diseases and 
in Palliative Care 
2. to measure of hypnosis's influence and efficacy, as an 
adjuvant therapy, on anxiety symptoms in severe chronic 
diseases and in Palliative Care 
3. to measure of hypnosis's influence and efficacy, as an 
adjuvant therapy, on the use of opioids in severe chronic 
diseases and in Palliative Care 
4. to demonstrate reliability and validity of the 
effectiveness of the use of hypnosis, and self-hypnosis to 
relief pain and anxiety in severe chronic illnesses and in 
Palliative Care for a long term follow-up (1 year and 2 
years). 
 
The first long-term follow-up at 1 year 
 
One of the aim of this research was to demonstrate reliability 
and validity of the effectiveness of the use of hypnosis, and self-
hypnosis to relief pain and anxiety in severe chronic illnesses 
and in Palliative Care for a long term follow-up (1 year and 2 
years). In fact, the scientific literature about clinical hypnosis in 
pain therapy and palliative care, lack about long term follow-ups 
about the efficacy during the time. 
The figures from 2 to 5 show the measure of the pain, anxiety 
and the use of the opioids in the group treated with clinical 
hypnosis, after the Primary long-term follow-up: one-year. We 
can observe the hypnosis's influence and efficacy, as an adjuvant 
therapy, on pain in the group treated with clinical hypnosis as 
adjuvant therapy added to the pharmachological therapy (figure 
2 and 3).  
In  Figure 3 we obsrve the group n. 1 treated with hypnosis as an 
adjuvant therapy, and his statistical significant decrease of VAS 
pain’ score, after 1year follow up in each of the 3 different types 
of diseases: cancer, neurological diseases ND, and reumathic 
diseases CRD: the efficacy of the therapy is homogeneus in the 
different diseases. 
We obtained a significant decreas on anxiety symptoms in the 
group treated with clinical hypnosis as adjuvant therapy added 
to the pharmachological therapy (figure 4, 5 and 6). 
In Figure 5 we observe the group n. 1 treated with hypnosis as 
an adjuvant therapy, and his statistical significant decrease of 
Hamilton anxiety score, after 1 year follow up in each of the 3 
different types of diseases: cancer, ND and CRD: the efficacy of 
the therapy is homogeneus in the different diseases. 
We obtained a significant decreas on the use of opioids in severe 
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chronic diseases and in Palliative Care (figure 7). 
In the Primary long-term one-year follow-up, we have decided 
to study also one item of the HAMA scale, the muscle 
contracture, because we observed that the patients with very 
severe diseases, at the end of life, in the 2 groups, presented an 
important muscular pain. We decided to study this item to 
observe if with the hypnosis intervention the hypnosis’ group 
could have muscular pain and contracture relieved (figure 6). 
The group n. 1 treated with hypnosis as an adjuvant therapy, had 
a statistical significant decrease of muscle contracture after 1 
year follow up. 
The figure 7 shows the significant statistical decrease of the use 
of opioids (pain-control medicines at 1year follow-up in the 
group-hypnosis. The most of the patients asked to doctor 
Brugnoli (the principal investigator) the permission to decrease 
the opioids they were using, because they obtained a good pain 
relief. 
Table 1 shows the characteristics of the 2 groups at the baseline 
and after 1-year follow-up we did not have drop-out. 
The Scores of pain, anxiety, and muscle contracture across the 2 
groups at baseline and at 1-year follow up. The score of VAS 
and Hamilton are homogeneous at the baseline in the 2 groups. 
We observe a significative decrease of pain, anxiety and muscle 
conctracture in the group-hypnosis compared to the control-
group (table 2a and 2b). 
The coefficients from the linear regression models: the hypnotic 
therapy and the VAS score at baselines have a significant and 
independent association with the decrease of the VAS score 
after 1 year. In particular, the persons who had the hypnotic 
treatment had also a decrease of 16 points in the VAS score 
compared to the group that had not the hypnotic treatment (table 
3). 
The coefficients from the quantile regression models: the 
hypnotic therapy and the Hamilton anxiety score at baselines 
have a significant and independent association with the decrease 
of the Hamilton anxiety score after 1 year. In particular, the 
group who had the hypnotic treatment had also a decrease of 7 
points in the Hamilton anxiety score compared to the group that 
had not the hypnotic treatment (table 4). 
Table n. 5 shows that only the 16% of the patients treated with 
hypnosis had to increase the pharmacological therapy, but the 
52% of the control group, had to increase the pharmacological 
therapy after 1 year. The use of opioids is less in people who 
practice hypnosis. Who practice hypnosis has a less risk of 60% 
to have to increase the pharmacological therapy, compared with 
the control group.  
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Data were summarized with means ± standard deviation (SD) or 
number (percentage), as appropiate. Comparisons of variables 
between groups were performed using the Person’s chi-squared, 
the Student’s T, or the Wilcoxon’s rank-sum tests, accordingly 
to the nature and the distribution of each variable. The 
associations of each variable with 1 year variations in VAS 
score, Hamilton’s score, and in pharmacological therapy were 
evaluated by linear, quantile, and binomial regression models, 
respectively.  
 
Follow-up after 1 year:   
 drop-out: none 
 GROUP N.1 = 25 patients treated with hypnosis  
 and comparison with GROUP N. 2 = 25 patients of the control group (no 
hypnosis) 
 
The following figures show the measure of the pain, anxiety and 
the use of the opioids in the group treated with clinical hypnosis, 
after the Primary long-term outcome: one-year follow-up. 
We can see: 
 the hypnosis's influence and efficacy, as an adjuvant 
therapy, on pain in the group treated with clinical 
hypnosis as adjuvant therapy added to the 
pharmachological therapy (figure 2 and 3) 
 the hypnosis's influence and efficacy, as an adjuvant 
therapy, on anxiety symptoms in the group treated 
with clinical hypnosis as adjuvant therapy added to 
the pharmachological therapy (figure 4, 5 and 6) 
 the hypnosis's influence and efficacy, as an adjuvant 
therapy, on the use of opioids in severe chronic 
diseases and in Palliative Care (figure 7) 
 In the Primary long-term outcome: one-year follow-
up, we have decided to study also one item of the 
HAMA scale, the muscle contracture, because we 
observed that the patients with very severe diseases, 
at the end of life, in the 2 groups, presented an 
important muscular pain. We decided to study this 
item to observe if with the hypnosis intervention the 
hypnosis’ group could have muscular pain and 
contracture relieved. 
 
The statistical analysis and correlations between group 1 
(hypnosis and self-hypnosis) and group 2 (no hypnosis) at the 
long-term follow up of 1 year. 
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Table 1 shows the Characteristics of the 2 groups at the baseline 
and after 1-year follow-up (no drop-out) 
Data are expressed in n (%) or mean ± SD. 
 
 
 
 
At the first 1 –year long term follow-up we did not had any 
drop-out. 
The study of the 2 groups of 25 patients each (total 50 patients 
studied after 1 year follow-up), were homogeneous for the sex, 
age and the types of the severe chronic diseases, the same of the 
baseline. 
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Figure 2: the group n. 1  treated with hypnosis as an adjuvant 
therapy, and his statistical significant decrease of VAS pain’ 
score, after 1 year follow up. 
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Figure 3: the group n. 1 treated with hypnosis as an adjuvant 
therapy, and his statistical significant decrease of VAS pain’ 
score, after 1year follow up in each of the 3 different types of 
diseases: cancer, neurological diseases ND, and reumathic 
diseases CRD: the efficacy of the therapy is homogeneus in the 
different diseases. 
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Figure 4: the group n. 1 treated with hypnosis as an adjuvant 
therapy, and his statistical significant decrease of Hamilton 
anxiety score, after 1 year follow up. 
 
Figure 5: the group n. 1 treated with hypnosis as an adjuvant 
therapy, and his statistical significant decrease of Hamilton 
anxiety score, after 1 year follow up in each of the 3 different 
types of diseases: cancer, ND and CRD: the efficacy of the 
therapy is homogeneus in the different diseases. 
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Anxiety and muscular contracture: 
Figure 6: at the first follow-up (1 year) we have studied the item 
of the HAMA about the muscle conctacture, because the patients 
with the most severe diseases (the advanced illnesses), presented 
a fibromyalgia syndrome associated to the chronic diseases.  
The group n. 1 treated with hypnosis as an adjuvant therapy, had 
a statistical significant decrease of muscle contracture after 1 
year follow up. 
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Figure 7: USE OF OPIOIDS 
The figure shows the significant statistical decrease of the use of 
opioids (pain-control medicines at 1year follow-up in the group-
hypnosis. The most of the patients asked to doctor Brugnoli (the 
principal investigator) the permission to decrease the opioids 
they were using, because they obtained a good pain relief. 
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Table 2 a and b shows the Scores of pain, anxiety, and muscle 
contracture across the 2 groups at baseline and at 1-year follow 
up. The score of VAS and Hamilton are homogeneous at the 
baseline in the 2 groups. We observe a significative decrease of 
pain, anxiety and muscle conctracture in the group-hypnosis 
compared to the control-group. 
 
 
 
Table 2a: Data expressed in mean ± SD; p-values from t test 
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Table 2b : Scores of pain, anxiety, and muscle contracture 
across the 2 groups at baseline and at 1-year follow up. The 
score of VAS and Hamilton are homogeneous at the baseline in 
the 2 groups. We observe a significative decrease of pain, 
anxiety and muscle conctracture in the group-hypnosis 
compared to the control-group. 
 
Data expressed in median (1st;3rd quartile); p-values from 
Mann-Whitney test 
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Table 3 shows the Variables associated with variations in VAS 
pain score. Coefficients from the linear regression models 
Table 3 shows coefficients from the linear regression models: 
the hypnotic therapy and the VAS score at baselines have a 
significant and independent association with the decrease of the 
VAS score after 1 year. In particular, the persons who had the 
hypnotic treatment had also a decrease of 16 points in the VAS 
score compared to the group that had not the hypnotic treatment. 
 
 
Table 3: Variables associated with variations in VAS pain 
score. Coefficients from the linear regression models 
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Table 4 shows coefficients from the quantile regression models: 
the hypnotic therapy and the Hamilton anxiety score at baselines 
have a significant and independent association with the decrease 
of the Hamilton anxiety score after 1 year. In particular, the 
group who had the hypnotic treatment had also a decrease of 7 
points in the Hamilton anxiety score compared to the group that 
had not the hypnotic treatment. 
 
Table 4: Variables associated with variations in Hamilton’s 
anxiety score. Coefficients from the quantile regression models  
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Table 5 shows the Variables associated with increase in 
pharmacological therapy (opioids). Adjusted risk ratios from the 
binomial. 
Table n. 5 shows that only the 16% of the patients treated with 
hypnosis had to increase the pharmacological therapy, but the 
52% of the control group, had to increase the pharmacological 
therapy after 1 year. The use of opioids is less in people who 
practice hypnosis. Who practice hypnosis has a less risk of 60% 
to have to increase the pharmacological therapy, compared with 
the control group.  
 
Table 5: Variables associated with increase in 
pharmacological therapy (opioids). Adjusted risk ratios from 
the binomial. 
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2 years long term follow-up 
 
Table 6 shows the Characteristics of eligible subjects who 
completed and didn’t complete (drop-out) the 2yr follow-up 
study.  
After 2 years, we have a total of 13 drop-out in the 2 groups:  
 7 drop-out in the hypnosis group   
 6 drop-out in the control group.  
The patients affected by cancer, enrolled at baseline in the 2 
groups = 13 
 6 patients in control group: 3 Breast cancer with multiple 
metastasis, 1 Colon cancer with multiple metastasis, 1 
Leukemia, 1 Lymphoma;   
7 patients in hypnosis group: 4 Breast cancer with multiple 
metastasis, 2 Leukemia, 1 Lymphoma. 
 
DROP OUT: 
 
CANCER  
n. 6 cancer patients, died for the cancer:  
Control group: 1 died for Breast cancer, 1 died for colon cancer. 
Group hypnosis: 2 died for Breast Cancer, 2 died for Leukemia. 
 
NEUROLOGICAL DISEASES 
n. 3 patients with the neurological diseases (multiple sclerosis) 
had an increase of the severity of the diseases and could not to 
come to the hospital anymore. They could not attend the 
hypnosis group and the control group could not to come to the 
hospital for pain therapy with the medicines and the foolow-up. 
2 patients with multiple sclerosis dropped out from the control 
group and 1 from hypnosis group. 
 
REUMATIC DISEASES 
n. 4 patients with the rheumatic diseases: 2 had an increase of 
the severity of the diseases and could not to come to the hospital 
anymore: they were patients of the hypnosis group. 
 1 patient of the control group would like to use anxiolitics and 
entered in the exclusion criteria; 1 patient of the control group 
avoided to do the follow-up at the second year (she avoided to 
come to the hospital to be cured). 
 
The second year we have studied the relationship of hypnosis 
on: 
- Pain relief 
- Anxiety relief 
- Use of opioids 
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These 3 are the aims of the research. 
In the secondary long-term outcome: two-years follow-up, we 
have decided do not study anymore the item of the HAMA 
scale, the muscle contracture, because we observed that the 
patients with the very severe diseases, at the end of life, that had 
in the first follow-up the muscular contracture, were the patients 
dropped out. This added study to the other 3 main aims of the 
research, at this point, would not have been important, because 
at the follow-up of 2 years, most of the patients of both the 2 
groups, remained in the study, was not suffering of contractures 
and fybromialgia syndrome. 
Table 6 shows the characteristics of eligible subjects who 
completed and didn’t complete (drop-out) the 2yr follow-up 
study. The Data are expressed in n (%) or mean ± SD 
In the secondary long-term outcome: two-years follow-up, we 
have decided do not study anymore the item of the HAMA 
scale, the muscle contracture, because we observed that the 
patients with the very severe diseases, at the end of life, that had 
in the first follow-up the muscular contracture, were the patients 
dropped out. This added study to the other 3 main aims of the 
research, at this point, would not have been important, because 
at the follow-up of 2 years, most of the patients of both the 2 
groups, remained in the study, was not suffering of contractures 
and fybromialgia syndrome. 
The decrease of the pain (VAS) was most important with the 
patient of the group hypnosis than in the control group 
(p=0.0001). We must remember that both the two groups of the 
patients were cured with a pharmacological therapy and 
hypnosis was an adjuvanrt therapy, added in the hypnosis 
gropup. The Hamilton score is decreased from 32.6 at baseline 
to 22.9 and 17.1 at the first and second follow-up in the 
hypnosis group. In the control group it is the same at baseline 
(29.8), after 1 year (26.1) and after 2 years (28.5). 
In both the measures of VAS and HAMA, we do not have 
differences between the different diseases: cancer, neurological 
diseases and rheumatic diseases, because the hypnosis 
intervention has the same therapeutic effect in the different 
diseases: the patients could have the same pain and anxiety relief 
in all the different diseases. 
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Table 6: Characteristics of eligible subjects who completed 
and did not complete (drop-out) the 2yr follow-up study. 
Data expressed in n (%) or mean ± SD 
 
The statistical analysis shows that the decrease of the pain 
(VAS) was most important with the patient of the group 
hypnosis than in the control group (p=0.0001). We must 
remember that both the two groups of the patients were cured 
with a pharmacological therapy and hypnosis was an adjuvanrt 
therapy, added in the hypnosis gropup. The Hamilton score is 
decreased from 32.6 at baseline to 22.9 and 17.1 at the first and 
second follow-up in the hypnosis group. In the control group it 
is the same at baseline (29.8), after 1 year (26.1) and after 2 
years (28.5). 
ANOVA shows that the difference between the two groups is 
statistically significant (p<0.0001). In both the measures of VAS 
and HAMA, we do not have differences between the different 
diseases: cancer, neurological diseases and rheumatic diseases, 
because the hypnosis intervention has the same therapeutic 
effect in the different diseases. 
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Table 7 : Assessment of subjects at baseline, 1-yr, and 2-yr 
follow-up: Data expressed in mean ± SD (n)  
 
 
Table 7 shows the Assessment of subjects at baseline, 1-yr, and 
2-yr follow-up. The 2 groups were homogeneus. 
The  p-value show in the table the relationship between the 2 
groups at 1 and 2 years follow-up. The 2 groups have very 
different score of VAS the first year and HAMA very different 
the second years. 
The statistical analysis with ANOVA underlines that the decreas 
for VAS is most important in the hypnosis group than in the 
control group (p=0.0001). 
The score of HAMA for anxiety decreases from da 32.6 at 
baseline to 22.9  and 17.1 at the follow-up  of 1 year and 2 year 
in the hypnosis group, while it is the same in the control group 
(29.8, 26.1, e 28.5 at baseline, 1 and 2 years). 
ANOVA underlines that the difference between the 2 groups is 
statistically significant (p<0.0001). 
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Figure 7: the VAS scores for Control and Hypnosis groups 
at baseline, year 1 and year 2, according to the type of 
disease suffered by subjects. 
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Table 8 and Figure 7 show the VAS scores for Control and 
Hypnosis groups at baseline, year 1 and year 2, according to the 
type of disease suffered by subjects.  
 
 
Table 8: VAS scores for Control and Hypnosis groups at 
baseline, year1 and year2, according to the type of disease 
suffered by subjects (mean ± sd) Data expressed in mean ± SD 
(n)  
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Figure 8 and 9 and Table 9  show the Hamilton scores (mean ± 
sd) for Control and Hypnosis groups at baseline, year1 and 
year2, according to the type of disease suffered by subjects: in 
all the severe diseases there is an important decrease for the the 
pain much more in the hypnosis group. 
 
 
Figure 8: Hamilton scores for Control and Hypnosis groups 
at baseline, year1 and year2, according to the type of disease 
suffered by subjects 
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Table 9 shows the Hamilton scores (mean ± sd) for Control 
and Hypnosis groups at baseline, year1 and year2, according 
to the type of disease suffered by subjects Data expressed in 
mean ± SD (n)  
 
 
Table 9  and figure 8, shows the Hamilton scores (mean ± sd) 
for Control and Hypnosis groups at baseline, year1 and year2, 
according to the type of disease suffered by subjects: in all the 
severe diseases there is an important decrease for the the anxiety 
only in the hypnosis group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
 
 
 
Figure 9 
 
 
 
 
 
Figure 9 and 10: Change in VAS and Hamilton score across 
treatment groups. 
 
 
Figure 10 
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Figure 11: Hamilton scores for Control and Hypnosis groups at 
baseline, year1 and year2, according to the type of disease 
suffered by subjects. 
 
Figure 12: VAS scores for Control and Hypnosis groups at 
baseline, year1 and year2, according to the type of disease 
suffered by subjects. 
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CHAPTER 4 
 
 
 
DISCUSSION AND CONCLUSIONS 
 
 
Discussion 
 
 
When a distressful injury or pathology is resistant to treatment 
and persists, when pain persists after the injury, or pathology has 
healed, and when medical science cannot identify the cause of 
pain, the task of medicine is to relieve suffering.  
We have observed the patients who performed hypnosis and 
self-hypnosis, not only had a significant decrease of pain, 
anxiety and the reduction of the use of opioids, but are more 
likely to adopt a positive lifestyle. 
The VAS scores for Control and Hypnosis groups at baseline, 
year1 and year2, according to the type of disease suffered by 
subjects, shows that in all the severe diseases there is an 
important decrease for the the pain much more in the hypnosis 
group. 
This is relevant, given that all patients in this study had received 
a pharmachological therapy for pain relief. 
The Hamilton scores (mean ± sd) for Control and Hypnosis 
groups at baseline, year1 and year2, according to the type of 
disease suffered by subjects shows in all the severe diseases 
there is an important decrease for the the anxiety only in the 
hypnosis group. 
For all the 3 types of disease, the reduction in both VAS and 
Hamilton scores was significantly greater in the subjects who 
were included in the hypnosis group, after 1 and 2 years follow-
up. Subjects in the hypnosis group were at lower risk of 
increasing the pharmacological treatment for pain control.   
Only 16% of the subjects included in the hypnosis group had to 
increase the pharmacological treatment for pain control after 1 
year, compared to 52% of the subjects in the control group. 
the patients of the group 1 (hypnosis) after a long term follow-
up 1 and 2 years of treatment with hypnosis as an adjuvant 
therapy for pain and anxiety, shows a significant statistical 
decrease of pain and anxiety compared with the control group, 
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and have a less risk to have to increase the pharmacological 
treatment with opioids for pain relief. 
In our clinical reflection of the results, we observe that many of 
them had a decrease of psychosomatic simptoms associated to 
pain and anxiety like imnsonnia, muscular contracture and 
depression. 
Many chronic pain patients often have reversed diurnal rhythms 
whereby they catnap during the day, reclining on couches and 
spent the night awake and restless. 
Hypnosis can often be quite successful in reestablishing a 
normal sleep pattern in such patients, often resulting in an 
improved sense of well-being and pain relief. 
Clinical hypnosis is a valid help for the patients with severe 
chronic diseases to enhance a sense of control, and improve pain 
and suffering relief, which is often lacking when someone has a 
chronic illness. 
Pain management with clinical hypnosis distills down to a very 
simple endpoint, patients’ relief and comfort. If the patient feels 
better, feels comforted, feels less stressed and more functional in 
life, and their practice pose no health risk, then supporting 
complementary and alternative therapies, creates a true holistic 
partnership in health care. 
Hypnotic phenomena comprise numerous brain systems, 
depending on the content of the hypnotic suggestion and the 
targeted function. Therefore hypnotic suggestions act through 
various means: while certain suggestions engage suppression 
mechanisms and yield subliminal processing, other suggestions 
interfere with the deployment of top-down amplification and 
elicit preconscious processing. During hypnotically induced 
subliminal and preconscious processing, hypnotic responses 
recruit frontal networks implicated in top-down attentional 
regulation, control and monitoring processes (Rainville et al., 
1999; Casale et al., 2012; Kihlstrom, 2013; Oakley and 
Halligan, 2013). As mentioned previously, these brain regions 
associate with the implementation of cognitive strategies to 
successfully comply with hypnotic suggestions. Subsequent 
neural effects putatively reflect the targeted function of the 
hypnotic suggestion (Oakley, 2008). For example, alterations of 
colour perception correspond with significant changes in the 
visual areas (Kosslyn et al., 2000; McGeown et al., 2012) and 
oscillatory modulations of posterior brain activity 70 to 120 
milliseconds post stimulus onset (Koivisto et al., 2013). These 
results suggest the presence of an early mechanism that 
supplants the actual representation of sensory events with the 
suggestion-related stored representation, subsequently producing 
alteration of perception and suppressing sensory input. In 
addition, because hypnosis supposedly elicits modifications of 
monitoring processes, perceptual alterations could also involve 
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modifications of reality monitoring – i.e., the cognitive ability to 
assess the authenticity of changes in perception (Bryant and 
Mallard, 2003, 2005; Landry M, Appourchaux K, Raz A., 2014; 
Landry M, Lifshitz M, Raz A., 2017). 
Clinical hypnosis can be considered a nonpharmacological 
intervention as “adjuvant” in pain therapy. 
In my profession, pain, suffering and death are always very 
close, and when I started to experiment on the process of clinical 
hypnosis in its deepest way, I discovered not only pain and 
anxiety relief, but also the awakening of the inner self with the 
acceptance of the death, at the end of life and in palliative care.  
Because the mechanisms of pain in cancer, chronic diseases and 
in Palliative Care, may be complex, involving several causes, 
such patients often have difficulty obtaining an adequate therapy 
(Baker TA, Krok-Schoen JL, McMillan SC., 2016; Brugnoli 
MP, Brugnoli A, Norsa A., 2006). 
In our clinical observation for 2 years of treatment with clinical 
hypnosis, we perceived from a clinical point of view, in patient 
treated with hypnosis other several benefits like: 
 have a good muscle relaxation of the 
body  
 have a good muscle relaxation of the 
mind (anxiety relief) 
 reduce anxiety in palliative care and at 
the end of life 
 reduce the ‘Total suffering’ 
 have a good acute and chronic pain relief 
 altered perception of pain. 
 facilitate new patterns of thoughts, 
feelings and consciousness 
 reduce depression 
 reduce sleep disturbances 
 reduce pre-operative anxiety (in cancer 
patients) 
 reframe or redefine a problem or 
situation with relisielce 
 bypass normal ego defenses 
 suggest solutions and new options 
 increase communication with family and 
other peole 
 improve mind-body relationship, as a 
psychotherapy 
 lighten up the "spiritual" dimension in 
dying patients 
 accept death and dying. 
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The hypnosis’ techniques, allow the patients’ mind to settle 
inward beyond thought to experience the source of thought, 
inner resilience to relief pain and anxiety in severe chronic 
illnesses.  
In this state of restful alertness, your brain functions with 
significantly greater coherence and your body gains deep rest 
(Austin, J. H.,1999). 
The aim of clinical hypnosis and self-hypnosis is to bring an 
inner  state of well-being within ourselves  and the world, in a 
positive mental and (at the end of life) spiritual way. This 
research has shown clinical  hypnosis to be helpful not only  for 
acute and chronic pain, but also to accept serenely the end of 
life. We did not measure this topic in our patients, but clinically 
we noted a very great difference between the patients of the 2 
groups. 
A hypnotherapist can teach to the patients the self-regulation 
skills. For instance, someone with arthritis or cancer pain, may 
learn to turn down pain like the volume on a radio. 
Hypnotherapy can be used to help manage chronic illness.  
Self-hypnosis can enhance a sense of control, and improve pain 
and suffering relief, which is often lacking when someone has a 
chronic illness. 
This research shows that hypnotherapy reduces pain, anxiety, 
and discomfort, and reduces the use of opioids. 
Pain is the major problem in the treatment of patients with 
chronic diseases and cancer. During prolonged illnesses, the best 
way that we can create that change our suffering, is to modify 
our thoughts, from being negative about positive.  
The positive discovery about clinical hypnosis, is that we are 
focusing within ourselves, and becoming free of negativity. 
Clinical hypnosis improves psychological resilience. It is an 
individual's tendency to cope with stress and adversity. This 
coping may result in the individual "bouncing back" to a 
previous state of normal functioning, or simply not showing 
negative effects. In all these instances, resilience is best 
understood as a process. It is often assumed to be a trait of the 
individual, an idea more typically referred to as "resiliency." 
Most research now, shows that resilience is the result of 
individuals being able to interact with their environments, and 
the processes that either promotes well-being or protects them 
against the overwhelming influence of risk factors.  
These processes can be individual coping with strategies, or may 
be helped by clinical hypnosis (Casula C., 2001).  
Clinical hypnosis’ techniques, simply involve a process of 
transforming ourselves,  our thoughts, and recognizing the 
negative thoughts, and changing them into beneficial and 
peaceful thoughts, not only psychologically, but also with a 
physical pain relief. (Erickson, M.H., 1959; De Sousa, R.,1987; 
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Brugnoli, M.P., Brugnoli, A., Norsa, A., 2006; Brugnoli, 
A.,2005; Linden JH., 1999; Casula C., 2001). 
The best attitude towards hypnosis, is to be very patient, as the 
mind does not always want to focus. Having a sense of 
expectation towards positive results, can create uncomfortable 
pressure and thus take away the enjoyment of the experience. By 
practicing hypnosis regularly, the person gains a wonderful 
sense of the suffering relief. 
Self- hypnosis is a self-healing processe: any form of pain is a 
sign of our negative thinking and dis- ease within our mind.  
If we don't attend to dis- ease in the mind, we may find that 
chronic suffering can lead to disease of the body (Fourie, 
D.P.,1997; Handel, DL., 2001; Patterson, D.R., 2010). 
This is that we have been proven by this scientific research.  
Nonpharmacologic approaches as hypnosis, are intended to 
supplement, not substitute for, the pharmacologic or invasive 
techniques described.  
Nonpharmacologic interventions are appropriate in chronic 
diseases, in cancer patients and in Palliative Care, for the patient 
who:  
1) finds such interventions appealing;  
2) expresses anxiety or fear, as long as the anxiety is not 
incapacitating or due to a medical or psychiatric condition that 
has a –non specific treatment;  
3) may benefit from avoiding or reducing drug therapy for pain 
and anxiety(e.g., history of adverse reactions, fear of or 
physiological reason to avoid oversedation);  
4) is likely to experience and need to cope with a prolonged 
interval of postoperative pain, particularly if punctuated by 
recurrent episodes of intense treatment, or procedure–related 
pain. 
5) has incomplete pain relief following appropriate 
pharmacologic interventions. 
During my research as pain therapist and palliative care 
physician, I was always very touched by the suffering and the 
death of my patients with cancer and severe chronic diseases, 
but I understood that clinical hypnosis could be an important 
empathetic and compassionate approach for the total suffering, 
as an adjuvant therapy. 
The suffering of these patients is not only physical but also 
psychological and spiritual, and clinical hypnosis can really help 
the patients with chronic diseases, in a state of ‘total pain’ at the 
end of life. 
Palliative care was perceived in the hypnosis group, to be more 
holistic and person-focused, even if it was a group therapy, with 
an emphasis on symptoms’ management. The group therapies 
with clinical hypnosis, were seen as following an empathetic and 
compassionate model, in contrast to the simply pharmacological 
97 
 
model experienced in the palliative care of the control group. An 
important statistical differences on the score of pain and anxiety 
were found after one year and two years of follow-up between 
participants in the hypnotical intervention and the control group. 
 
 
Limitations and recommendations for future researches 
 
The limitations of the current research preclude our ability to 
draw strong conclusions to inform clinical practice or public 
policy regarding optimal use of the hypnosis and self-hypnosis 
therapies for severe chronic diseases and in palliative care. 
 The following limitations are evidence point to numerous 
opportunities to improve future research. Questions remain 
about the efficacy, comparative effectiveness, and differential 
response among subgroup populations.  
We would have compare a third group of patients studied with 
alternative/complementary medicine, or psychotherapy, but we 
did not have enough patients to enroll that could met the 
inclusion criteria. 
One of the most pertinent questions regarding clinical hypnosis 
therapies for pain and anxiety is: What effects might one expect 
of a given intervention relative to no intervention? This 
clinically relevant question is best addressed by a randomized 
clinical trial. However, for an ethical choose, we decided to 
respect the enthusiasm of patients with severe chronic diseases, 
to add self-hypnosis to the pharmacological terapy: expectations 
and motivations could be also a bias. But we could observe that 
the patient of hypnosis group, died for cancer, developed better 
resilience and self growth at the end of life, respect to the 
patients of control group. 
Although this therapeutic approach has not been used widely, 
such strategies merit consideration as an alternative to increase 
medicines. 
Another pertinent inquiry is: to what extent might placebo, or 
nonspecific effects account for observed clinical outcomes? This 
question can be hard to answer for CAM therapies, like 
hypnosis, for which it may be difficult to design a sham 
procedure that is both truly inert and that appears sufficiently 
similar to the active intervention to isolate the specific effect of 
the intervention. The fields of psychotherapy research have long 
grappled with similar issues. Strong recommendations and 
methodological guidelines now exist to guide these efforts 
(Schnurr PP., 2007). 
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Although more costly and challenging to conduct, comparative 
effectiveness designs also may be indicated to give patients and 
clinicians the most direct evidence about competing treatment 
options.  
We must also consider that is difficult compare the exat 
interaction of the many different chemotherapies on pain relief. 
All our cancer patients was in a stage of severe disease and all of 
them had almost a cycle of chemotherapy in the 2 years of the 
follow-up. However, we must consider also that they were 
shared equitably in the two groups: 28% in the hypnosis group 
and 24% in the control group.  
 
Conclusions  
 
Several studies are needed to improve the knowledge of clinical 
hypnosis in Palliative Care. Advances in health information  and 
studies are enabling a transformation in health research that 
could facilitate studies that were not feasible in the past, and 
thus lead to new insights regarding health and disease. 
The greatest limit to its use in today’s palliation is the lack of 
education by hospital personnel in its use, and their resulting 
failure to recommend its use for patients. There are also too few 
hypnotherapists with specific training and experience in this 
field. 
Clinical Hypnosis in Palliative care offers patients in pain not a 
measurable quantity of days, but quality of life, with pain and 
anxiety relief, and ready to accept the natural dying process 
characterized by the failing of the body. 
 
Key Messages 
 
Hypnosis offers the opportunity to relief : 
 Physical pain relief (Patterson, D.R., 2010; Patterson, D.R., Jensen, M.P., 
2005; Landry M, Lifshitz M, Raz A., 2017). 
 Psychological anxiety and spiritual suffering relief (Perez-De-Albeniz, A., 
Jeremy H., 2000; Linden JH, Bhardwaj A, Anbar RD., 2006). 
 the reduction of the use of the opioids (Berger MM, Davadant M, Marin C, 
Wasserfallen JB, Pinget C, Maravic P, Koch N, Raffoul W, Chiolero RL., 
2010). 
 Clinical hypnosis is a valid therapy for a long treatment (we have a follow-
up of 2 years) 
 clinical hypnosis is an  interdisciplinary therapy and is centered around the 
quality of life of the patients. 
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